[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 114
1. Farah-Klibi F, Ferchiou M, Kourda J, El Amine O, Ferjaoui M, Ben Jilani S, Zermani R: [Parotid basal cell adenoma of membranous type]. Tunis Med; 2009 Feb;87(2):149-51
MedlinePlus Health Information. consumer health - Sarcoidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Parotid basal cell adenoma of membranous type].
  • [Transliterated title] Adenome a cellules basales de type membraneux de la parotide.
  • INTRODUCTION: Basal cell adenoma (BCA) is a rare benign neoplasm characterized by the basaloid appearance of the tumour cells and the lack of myxo-chondroid stromal component present in pleomorphic adenoma.
  • AIM: We report a case of basal cell adenoma of membranous type, highly suspected of malignancy because of the presence of mediastinal lymph nodes and pulmonary nodules which finally were related to an associated sarcoidosis.
  • So the diagnosis of metastatic malignant salivary gland tumor was suspected.
  • Finally, the histological examination concluded to a basal cell adenoma of membranous type with sarcoidosis granulomas in the parotid and in the lymph nodes.
  • CONCLUSION: The BCA is a benign tumor located generally in the parotid gland.
  • When the malignancy is suspected, like in our case, this tumor must be differentiated from the basal cell adenocarcinoma using histological criteria.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19522450.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


2. Iczkowski KA, Montironi R: Adenoid cystic/basal cell carcinoma of the prostate strongly expresses HER-2/neu. J Clin Pathol; 2006 Dec;59(12):1327-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic/basal cell carcinoma of the prostate strongly expresses HER-2/neu.
  • Adenoid cystic/basal cell carcinoma (ACBCC) is a rare neoplasm in the prostate.
  • Benign acini expressed HER-2/neu only in the basal layer.
  • The finding of strong, consistent HER-2/neu expression in ACBCC suggests that treatment with Herceptin (trastuzumab) may be effective in patients with this rare tumour.
  • [MeSH-major] Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Basal Cell / metabolism. Mixed Tumor, Malignant / metabolism. Prostatic Neoplasms / metabolism. Receptor, ErbB-2 / metabolism
  • [MeSH-minor] Adult. Aged. Gene Expression. Humans. In Situ Hybridization. Male. Middle Aged. RNA, Messenger / genetics. RNA, Neoplasm / genetics


3. Minicucci EM, de Campos EB, Weber SA, Domingues MA, Ribeiro DA: Basal cell adenoma of the upper lip from minor salivary gland origin. Eur J Dent; 2008 Jul;2(3):213-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenoma of the upper lip from minor salivary gland origin.
  • Basal cell adenoma is an uncommon benign salivary gland neoplasm, presenting isomorphic basaloid cells with a prominent basal cell layer.
  • Taking into account that basal cell adenomas represent 1% of all salivary gland tumors, being the majority of cases in the parotid glands, the goal of this paper is to report a case of basal cell adenoma of the upper lip arising from minor salivary gland.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oral Maxillofac Surg. 2005 Jul;34(5):533-6 [16053874.001]
  • [Cites] J Oral Maxillofac Surg. 2005 Jun;63(6):805-10 [15944978.001]
  • [Cites] Diagn Cytopathol. 1999 Jul;21(1):30-4 [10405805.001]
  • [Cites] J Oral Pathol Med. 1996 Jan;25(1):1-4 [8850349.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 Jul;32B(4):251-9 [8776422.001]
  • [Cites] Semin Diagn Pathol. 1996 May;13(2):95-103 [8734415.001]
  • [Cites] J Craniomaxillofac Surg. 2000 Feb;28(1):56-61 [10851675.001]
  • [Cites] J Clin Pathol. 1992 Sep;45(9):834-5 [1401223.001]
  • [Cites] J Oral Pathol. 1985 Jul;14(6):500-9 [2991488.001]
  • [Cites] Acta Otolaryngol Suppl. 1969;263:155-9 [5269030.001]
  • [Cites] Rev Hosp Clin Fac Med Sao Paulo. 2002 Nov-Dec;57(6):271-6 [12612759.001]
  • [Cites] Oral Oncol. 2001 Jun;37(4):365-8 [11337269.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1995 May;31B(3):197-201 [7549761.001]
  • (PMID = 19212550.001).
  • [ISSN] 1305-7456
  • [Journal-full-title] European journal of dentistry
  • [ISO-abbreviation] Eur J Dent
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  • [Other-IDs] NLM/ PMC2635906
  • [Keywords] NOTNLM ; Basal cell adenoma / Immunohistochemistry / Minor salivary gland
  •  go-up   go-down


Advertisement
4. Scheinfeld N: Review of scalp alopecia due to a clinically unapparent or minimally apparent neoplasm (SACUMAN). Acta Derm Venereol; 2006;86(5):387-92
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review of scalp alopecia due to a clinically unapparent or minimally apparent neoplasm (SACUMAN).
  • Neoplastic cells, both malignant and benign, local occurring and metastatic, can cause alopecia of the scalp.
  • However, the infiltration of neoplastic cells is sometimes not florid; a condition known as "scalp alopecia due to a clinically unapparent or minimally apparent neoplasm" (SACUMAN).
  • The most common neoplasm in which an uncomplicated, minimally or unapparent scalp alopecia occurs and no infiltrate of cancer is suspected is metastatic breast carcinoma.
  • Other causes include squamous and basal cell carcinomas, angiosarcoma, gastric carcinoma, placental site tromphoblastic tumor, and mycosis fungoides.
  • Dermatologists must be aware that in rare cases a bland scalp alopecia can represent a new or recurring, local or metastatic neoplasm.
  • [MeSH-minor] Breast Neoplasms / pathology. Carcinoma, Basal Cell / pathology. Cicatrix / pathology. Hemangiosarcoma / pathology. Humans. Keloid / complications. Keloid / pathology. Lymphoma / pathology. Scalp / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16983449.001).
  • [ISSN] 0001-5555
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Norway
  • [Number-of-references] 56
  •  go-up   go-down


5. Pham TT, Selim MA, Burchette JL Jr, Madden J, Turner J, Herman C: CD10 expression in trichoepithelioma and basal cell carcinoma. J Cutan Pathol; 2006 Feb;33(2):123-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD10 expression in trichoepithelioma and basal cell carcinoma.
  • BACKGROUND: Trichoepithelioma (TE) is a benign neoplasm that shares both clinical and histologic features with basal cell carcinoma (BCC).
  • Cases were analyzed for pattern of CD10 expression by tumor cells and surrounding stroma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / metabolism. Neoplasms, Basal Cell / metabolism. Neprilysin / metabolism. Skin Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16420307.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


6. Nakabayashi M, Shomori K, Kiya S, Shiomi T, Nosaka K, Ito H: Tubular-trabecular type Basal cell adenoma of the parotid gland: a patient report. Yonago Acta Med; 2010 Sep;53(3):65-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubular-trabecular type Basal cell adenoma of the parotid gland: a patient report.
  • Basal cell adenoma (BCA) is an uncommon benign salivary gland neoplasm that includes isomorphic basaloid cells.
  • The present patient demonstrated a few tumor nests in the fibrous capsule, and her tumor was larger than usual.
  • Histopathologically, the tumor was characterized by multiple duct-like structures and tubular-trabecular masses composed of small isomorphic cells with hyperchromatic, round nuclei and an eosinophilic cytoplasm.
  • It was difficult to determine whether the ductal structures noted in the tumor capsule were invasive.
  • By immunohistochemistry, tumor cells of the tubular nests were positive for cytokeratin 7 and that the outer cells of tubular nests were positive for alpha smooth muscle actin (αSMA) and calponin.
  • Tumor cells were immuno-negative for S-100 protein and glial fibrillary acidic protein.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24031120.001).
  • [ISSN] 0513-5710
  • [Journal-full-title] Yonago acta medica
  • [ISO-abbreviation] Yonago Acta Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Other-IDs] NLM/ PMC3763784
  • [Keywords] NOTNLM ; basal cell adenoma / immunohistochemistry / parotid gland
  •  go-up   go-down


7. Bechert CJ, Stern JB: Basal cell carcinoma with perineural invasion: reexcision perineural invasion? J Cutan Pathol; 2010 Mar;37(3):376-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma with perineural invasion: reexcision perineural invasion?
  • BACKGROUND: Perineural invasion (PI) in basal cell and squamous cell carcinomas, especially of the head and neck, has been reported to indicate an increased morbidity.
  • Reexcision perineural invasion (RPI), a benign mimic of tumoral perineural invasion, may present a difficult histologic differential diagnosis.
  • METHODS: We surveyed the medical literature for PI occurring in basal cell carcinomas to investigate the degree to which the reported cases occurred in reexcision specimens vs. primary biopsy specimens.
  • RESULTS: We found large retrospective studies of 14,120 basal cell carcinomas evaluated for PI in which 310 cases of PI were identified (2.2%), and 20 sporadic case reports of basal cell carcinomas with PI.
  • Of 310 cases of basal cell carcinoma with PI, 196 (63%) were in reexcision specimens.
  • CONCLUSION: The high percentage of PI occurring in reexcision specimens vs. primary excisions may indicate that many of the reported cases of basal cell carcinomas with PI are actually examples of RPI.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Neoplasm Invasiveness / pathology. Neoplasm Seeding. Skin Neoplasms / pathology
  • [MeSH-minor] Biopsy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Humans. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Reoperation. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Cutan Pathol. 2011 Jan;38(1):76-7 [20840330.001]
  • [CommentIn] J Cutan Pathol. 2012 Nov;39(11):1047-8 [22830947.001]
  • [CommentIn] J Cutan Pathol. 2011 Jan;38(1):78-9 [20860728.001]
  • (PMID = 19615028.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


8. Navarrete Isidoro O, Abad Fernández A, López Vime R, Jara Chinarro B, Juretschke Moragues MA: [Pulmonary metastasis of Basal cell carcinoma of the skin]. Arch Bronconeumol; 2005 Mar;41(3):169-71
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary metastasis of Basal cell carcinoma of the skin].
  • [Transliterated title] Metástasis pulmonares de un carcinoma basocelular cutáneo.
  • Basal cell carcinoma of the skin is a common neoplasm usually considered benign.
  • We report the case of a 41-year old man diagnosed with lung metastasis secondary to base cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / secondary. Lung Neoplasms / secondary. Skin Neoplasms

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15766469.001).
  • [ISSN] 0300-2896
  • [Journal-full-title] Archivos de bronconeumología
  • [ISO-abbreviation] Arch. Bronconeumol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


9. Arshad AR, Azman WS, Kreetharan A: Solitary sebaceous nevus of Jadassohn complicated by squamous cell carcinoma and basal cell carcinoma. Head Neck; 2008 Apr;30(4):544-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary sebaceous nevus of Jadassohn complicated by squamous cell carcinoma and basal cell carcinoma.
  • BACKGROUND: Sebaceous nevus is a benign congenital epidermal nevus.
  • Its association with basal cell carcinoma is well known.
  • METHOD: This is a case report of sebaceous carcinoma complicated by both basal cell carcinoma and squamous cell carcinoma.
  • RESULTS: The behavior of this tumor is very aggressive, resulting in poor prognosis.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Neoplasms, Multiple Primary / pathology. Nevus, Sebaceous of Jadassohn / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Fatal Outcome. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Surgical Flaps

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Nevus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17972311.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Naumann IC, Cordes SR: Giant basal cell carcinoma of the forehead with extensive intracranial involvement. Ann Otol Rhinol Laryngol; 2007 Sep;116(9):663-6
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant basal cell carcinoma of the forehead with extensive intracranial involvement.
  • Basal cell carcinoma (BCC) is the most common malignant skin lesion and is frequently curatively treated with local excision.
  • Despite its fairly benign growth pattern, BCC should never be underestimated, and care should be taken not only in the complete primary excision but also in cancer surveillance.
  • [MeSH-major] Brain Neoplasms / pathology. Carcinoma, Basal Cell / pathology. Forehead. Head and Neck Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy. Diagnosis, Differential. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Neoplasm Recurrence, Local / diagnostic imaging. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neurosurgical Procedures / methods. Reconstructive Surgical Procedures / methods. Severity of Illness Index. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17926588.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Zaballos P, Llambrich A, Puig S, Malvehy J: Dermoscopy is useful for the recognition of benign-malignant compound tumours. Br J Dermatol; 2005 Sep;153(3):653-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermoscopy is useful for the recognition of benign-malignant compound tumours.
  • In cases where a malignant neoplasm exists in association with a benign lesion it is important to make an accurate diagnosis in order to treat the lesions correctly.
  • We describe the dermoscopic characteristics of various collision or compound tumours that were composed of benign and malignant neoplasms: two cases of seborrhoeic keratosis associated with basal cell carcinoma, two cases of melanocytic naevus and basal cell carcinoma and one case of dermatofibroma associated with basal cell carcinoma.
  • [MeSH-minor] Adult. Aged. Carcinoma, Basal Cell / diagnosis. Diagnosis, Differential. Female. Histiocytoma, Benign Fibrous / diagnosis. Humans. Keratosis, Seborrheic / diagnosis. Male. Middle Aged. Nevus, Pigmented / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16120160.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 14
  •  go-up   go-down


12. Weyers W, Hörster S, Diaz-Cascajo C: Tumor of follicular infundibulum is Basal cell carcinoma. Am J Dermatopathol; 2009 Oct;31(7):634-41
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor of follicular infundibulum is Basal cell carcinoma.
  • Tumor of follicular infundibulum (TFI) is currently thought to be a benign epithelial neoplasm with follicular differentiation.
  • It is encountered commonly in association with basal cell carcinoma (BCC), often as an incidental finding.
  • [MeSH-major] Carcinoma, Basal Cell / classification. Carcinoma, Basal Cell / pathology. Skin Neoplasms / classification. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19652582.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. McGregor DH, Cherian R, Romanas MM, Ulusarac O, Mathur SC, Feldman MM: Amelanotic malignant melanoma: two collision tumors presenting as basal cell carcinoma and atypical fibroxanthoma. Ann Clin Lab Sci; 2008;38(2):157-62
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amelanotic malignant melanoma: two collision tumors presenting as basal cell carcinoma and atypical fibroxanthoma.
  • One patient is a 79-yr-old male with an 8.7 x 5.5 x 4.5 cm polypoid lesion that on shave biopsy was diagnosed as basal cell carcinoma.
  • Subsequent excision showed that the lesion was largely composed of amelanotic melanoma underlying a relatively small and thin basal cell carcinoma, and this probably would have been demonstrated in a punch (rather than shave) biopsy.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Histiocytoma, Benign Fibrous / diagnosis. Melanoma, Amelanotic / diagnosis. Neoplasms, Multiple Primary / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Humans. Immunohistochemistry. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18469362.001).
  • [ISSN] 1550-8080
  • [Journal-full-title] Annals of clinical and laboratory science
  • [ISO-abbreviation] Ann. Clin. Lab. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor
  •  go-up   go-down


14. Kawata R, Yoshimura K, Lee K, Araki M, Takenaka H, Tsuji M: Basal cell adenoma of the parotid gland: a clinicopathological study of nine cases--basal cell adenoma versus pleomorphic adenoma and Warthin's tumor. Eur Arch Otorhinolaryngol; 2010 May;267(5):779-83
Genetic Alliance. consumer health - Warthin's tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenoma of the parotid gland: a clinicopathological study of nine cases--basal cell adenoma versus pleomorphic adenoma and Warthin's tumor.
  • The aim of this study is to investigate the clinical and pathological characteristics of basal cell adenoma (BCA) and to compare the diagnosis/treatment of BCA with those of Warthin's tumor (WT) and pleomorphic adenoma (PA).
  • Among 192 patients with benign tumors of the parotid gland who underwent surgery, 9 had BCA.
  • All of these tumors showed a benign pattern on computed tomography and magnetic resonance imaging.
  • Considering the gender difference, tumor site, and age, it is necessary to differentiate BCA from PA rather than from WT.
  • BCA is the third most common of the benign parotid tumors, following WT and PA, although its incidence is low.
  • When PA and WT are ruled out by FNAB after a tentative diagnosis of benign tumor has been based on imaging findings, BCA should be considered.
  • [MeSH-minor] Adult. Aged. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Cytopathol. 2007 Feb;35(2):85-90 [17230571.001]
  • [Cites] Acta Otolaryngol. 1998 Jul;118(4):588-93 [9726688.001]
  • [Cites] Arch Klin Exp Ohren Nasen Kehlkopfheilkd. 1967;189(3):302-16 [5595712.001]
  • [Cites] Radiat Med. 2004 Jul-Aug;22(4):260-4 [15468947.001]
  • [Cites] Cancer. 1982 Aug 15;50(4):736-45 [6284339.001]
  • [Cites] Br J Radiol. 2005 Jul;78(931):642-5 [15961849.001]
  • [Cites] Med Oral Patol Oral Cir Bucal. 2006 Mar 01;11(2):E206-9 [16505803.001]
  • [Cites] Cancer. 1998 Feb 1;82(3):439-47 [9452259.001]
  • (PMID = 19908055.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


15. Bornstein MM, Filippi A, Altermatt HJ, Lambrecht JT, Buser D: [The odontogenic keratocyst--odontogenic cyst or benign tumor?]. Schweiz Monatsschr Zahnmed; 2005;115(2):110-28
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The odontogenic keratocyst--odontogenic cyst or benign tumor?].
  • [Transliterated title] Die odontogene Keratozyste--odontogene Zyste oder benigner Tumor?
  • Multiple odontogenic keratocysts are a well-recognized feature of the nevoid basal cell carcinoma syndrome.
  • This led to the tentative suggestion that the keratocyst might be a benign cystic neoplasm rather than simply an odontogenic cyst.

  • MedlinePlus Health Information. consumer health - Jaw Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15771334.001).
  • [ISSN] 0256-2855
  • [Journal-full-title] Schweizer Monatsschrift fur Zahnmedizin = Revue mensuelle suisse d'odonto-stomatologie = Rivista mensile svizzera di odontologia e stomatologia
  • [ISO-abbreviation] Schweiz Monatsschr Zahnmed
  • [Language] FRE; GER
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 68238-35-7 / Keratins
  • [Number-of-references] 69
  •  go-up   go-down


16. Katase N, Nagatsuka H, Tsujigiwa H, Gunduz M, Tamamura R, Pwint HP, Rivera RS, Nakajima M, Naomoto Y, Nagai N: Analysis of the neoplastic nature and biological potential of sporadic and nevoid basal cell carcinoma syndrome-associated keratocystic odontogenic tumor. J Oral Pathol Med; 2007 Oct;36(9):550-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of the neoplastic nature and biological potential of sporadic and nevoid basal cell carcinoma syndrome-associated keratocystic odontogenic tumor.
  • BACKGROUND: Keratocystic odontogenic tumor (KCOT), also known as odontogenic keratocyst, is a benign cystic neoplasm, which may be associated with nevoid basal cell carcinoma syndrome (NBCCS) and if it does, will occur as multiple cystic lesions.
  • [MeSH-major] Basal Cell Nevus Syndrome / enzymology. Glucuronidase / biosynthesis. Odontogenic Cysts / enzymology. Odontogenic Tumors / enzymology
  • [MeSH-minor] Dentigerous Cyst / enzymology. Gene Expression Regulation, Neoplastic. Heparan Sulfate Proteoglycans / metabolism. Humans. Immunohistochemistry. In Situ Hybridization. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17850439.001).
  • [ISSN] 0904-2512
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Heparan Sulfate Proteoglycans; EC 3.2.1.- / heparanase; EC 3.2.1.31 / Glucuronidase
  •  go-up   go-down


17. Misago N, Mori T, Narisawa Y: Nestin expression in stromal cells of trichoblastoma and basal cell carcinoma. J Eur Acad Dermatol Venereol; 2010 Nov;24(11):1354-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nestin expression in stromal cells of trichoblastoma and basal cell carcinoma.
  • BACKGROUND: Both trichoblastoma and basal cell carcinoma (BCC) are considered to be a benign and malignant neoplasm of follicular germinative cells respectively.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Intermediate Filament Proteins / metabolism. Nerve Tissue Proteins / metabolism. Sebaceous Gland Neoplasms / metabolism. Skin Neoplasms / metabolism. Stromal Cells / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20337823.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin
  •  go-up   go-down


18. Choi CW, Park HS, Kim YK, Lee SH, Cho KH: Elastic fiber staining and cytokeratin 15 expression pattern in trichoepithelioma and basal cell carcinoma. J Dermatol; 2008 Aug;35(8):499-502
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elastic fiber staining and cytokeratin 15 expression pattern in trichoepithelioma and basal cell carcinoma.
  • Trichoepithelioma (TE) is a benign neoplasm of the skin that resembles basal cell carcinoma (BCC) in its clinical and histological features.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Elastic Tissue / pathology. Keratin-15 / analysis. Neoplasms, Basal Cell / diagnosis. Skin Neoplasms / diagnosis. Staining and Labeling

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18789069.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Keratin-15
  •  go-up   go-down


19. Shimanovich I, Krahl D, Rose C: Trichoadenoma of Nikolowski is a distinct neoplasm within the spectrum of follicular tumors. J Am Acad Dermatol; 2010 Feb;62(2):277-83
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trichoadenoma of Nikolowski is a distinct neoplasm within the spectrum of follicular tumors.
  • BACKGROUND: Trichoadenoma is a rare benign follicular tumor first described by Nikolowski 50 years ago.
  • In trichoadenoma the cystic component predominates, while desmoplastic trichoepithelioma is a mostly solid neoplasm.
  • OBJECTIVE: The aim of this study was to investigate whether the morphologic overlap between trichoadenoma and desmoplastic trichoepithelioma translates into a similar immunohistochemical profile.
  • Trichoadenoma is a distinct follicular tumor related but not identical to desmoplastic trichoepithelioma.
  • [MeSH-major] Neoplasms, Basal Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Female. Head and Neck Neoplasms / pathology. Humans. Immunohistochemistry. Keratin-20 / metabolism. Male. Merkel Cells / pathology. Middle Aged. Neoplasms, Fibroepithelial / pathology. Receptors, Androgen / metabolism. Skin / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20115950.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AR protein, human; 0 / Biomarkers, Tumor; 0 / Keratin-20; 0 / Receptors, Androgen; 0 / human epithelial antigen-125
  •  go-up   go-down


20. Ali TZ, Epstein JI: Basal cell carcinoma of the prostate: a clinicopathologic study of 29 cases. Am J Surg Pathol; 2007 May;31(5):697-705
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of the prostate: a clinicopathologic study of 29 cases.
  • We studied 29 cases of basal cell carcinoma of the prostate including what others call adenoid cystic carcinoma of the prostate.
  • Other patterns included: basal cell hyperplasialike in 9 cases (32%); small tubules occasionally lined by a hyaline rim in 9 cases (32%), with 4 of these cases also demonstrating intermingling cords of cells; and large solid nests in 8 cases (28.5%), 5 of which had central necrosis.
  • Infiltration around benign glands was seen in 10 (36%) cases, with predominantly small nests and AC-P.
  • Perineural and vascular invasion was seen in 2 basal cell carcinomas with large basaloid nests.
  • Basal cell markers (HMWCK, p63) either:.
  • Basal cell carcinomas are rare tumors with a broad morphologic spectrum.
  • The most common morphology among those with an aggressive behavior is large solid nests more often with central necrosis, high Ki67%, and less staining with basal cell markers.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Biopsy, Needle. Combined Modality Therapy. Humans. Male. Middle Aged. Mitosis. Neoplasm Recurrence, Local. Retrospective Studies. Transurethral Resection of Prostate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460452.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


21. Plaza JA, Wakely PE Jr, Suster S: Lipoblastic nerve sheath tumors: report of a distinctive variant of neural soft tissue neoplasm with adipocytic differentiation. Am J Surg Pathol; 2006 Mar;30(3):337-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lipoblastic nerve sheath tumors: report of a distinctive variant of neural soft tissue neoplasm with adipocytic differentiation.
  • Benign nerve sheath tumors of soft tissue can occasionally adopt unusual or unfamiliar morphologic appearances that may introduce difficulties for diagnosis, such as multinucleation, bizarre nuclei, intranuclear vacuoles, and other degenerative changes.
  • Tumor cells adopting a signet-ring or lipoblast-like configuration, however, are mostly associated with epithelial malignancies, liposarcoma and melanoma, and have been only rarely observed in spindle cell tumors of soft tissue.
  • We report 5 cases of benign nerve sheath neoplasms that displayed prominent signet-ring cells with lipoblast-like features.
  • Four tumors predominantly showed features of schwannoma and one of neurofibroma; however, intimately admixed with the spindle cell population, there were also numerous scattered mature adipocytes as well as lipoblast-like cells displaying a signet-ring cell appearance.
  • The signet-ring cells contained large cytoplasmic lipid droplets that displaced the nuclei to the periphery, consistent with lipoblastic differentiation, whereas complex, interdigitating cytoplasmic processes covered by basal lamina material characteristic of nerve sheath differentiation could be identified in the spindle cells.
  • The presence of mature fat and signet-ring lipoblast-like cells within a nerve sheath neoplasm is quite rare and may signify a process of aberrant differentiation.
  • Neurogenic tumors should be added in the differential diagnosis of spindle cell tumors capable of displaying prominent signet-ring cell features.
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Carcinoma, Signet Ring Cell / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Microscopy, Electron, Transmission. Middle Aged

  • Genetic Alliance. consumer health - Nerve sheath neoplasm.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16538053.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Chen WL, Yang ZH, Huang ZQ, Chai Q, Zhang DM: Facial contour reconstruction after benign tumor ablation using reverse facial-submental artery deepithelialized submental island flaps. J Craniofac Surg; 2010 Jan;21(1):83-6
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Facial contour reconstruction after benign tumor ablation using reverse facial-submental artery deepithelialized submental island flaps.
  • Reverse facial-submental artery deepithelialized submental island flaps were used for reconstructing facial contour deformities in 5 patients after benign tumor ablation.
  • Recurrent pleomorphic adenoma in the cheek and inferior temple was present in 3 patients, and recurrent basal cell adenoma was present in 1.
  • The flap can be used reliably for facial contour reconstruction of middle and upper facial contour deformities after benign tumor ablation in the cheek and inferior temple.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Facial Neoplasms / surgery. Reconstructive Surgical Procedures / methods. Surgical Flaps / blood supply
  • [MeSH-minor] Adult. Cheek. Female. Forehead. Humans. Male. Neoplasm Recurrence, Local / surgery. Postoperative Complications. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20061969.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Brailey LL, Davis T, Kolker SE, Murry TC, Thomas D, Bale AE, Ruhoy SM: Congenital linear unilateral basal cell nevus: a case report with patched gene molecular studies. J Cutan Pathol; 2007 Jan;34(1):65-70
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital linear unilateral basal cell nevus: a case report with patched gene molecular studies.
  • BACKGROUND: Linear unilateral basal cell nevus represents a linear collection of macules and papules histologically similar to basal cell carcinoma but with benign clinical behavior.
  • We describe a patient who initially presented at the age of 6 months with a unilateral linear basal cell nevus on the right flank.
  • The differential diagnosis included the nevoid basal cell carcinoma syndrome.
  • Constitutional PTCH mutations are causative of the nevoid basal cell carcinoma syndrome, and somatic PTCH mutations are found in the vast majority of basal cell carcinomas.
  • Somatic SMO mutations have also been found in some basal cell carcinomas.
  • RESULTS: Histologic examination revealed features initially indistinguishable from basal cell carcinoma.
  • CONCLUSION: Molecular examination indicates that the PTCH and SMO genes are not involved in the pathogenesis of the patients' congenital linear unilateral basal cell nevus.
  • Furthermore, we discuss the relationship between linear basal cell nevus and basaloid follicular hamartoma.
  • [MeSH-minor] DNA, Neoplasm. Diagnosis, Differential. Humans. Infant. Loss of Heterozygosity. Microsatellite Repeats. Mutation. Receptors, Cell Surface / genetics. Receptors, G-Protein-Coupled / genetics

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Moles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17214858.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Receptors, Cell Surface; 0 / Receptors, G-Protein-Coupled; 0 / SMO protein, human; 0 / patched receptors
  •  go-up   go-down


24. Katona TM, Ravis SM, Perkins SM, Moores WB, Billings SD: Expression of androgen receptor by fibroepithelioma of Pinkus: evidence supporting classification as a basal cell carcinoma variant? Am J Dermatopathol; 2007 Feb;29(1):7-12
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of androgen receptor by fibroepithelioma of Pinkus: evidence supporting classification as a basal cell carcinoma variant?
  • The classification of fibroepithelioma of Pinkus as basal cell carcinoma or trichoblastoma remains controversial.
  • Immunohistochemical stains for androgen receptor may be useful in differentiating basal cell carcinoma from trichoepithelioma or trichoblastoma.
  • We studied androgen receptor expression in 13 fibroepitheliomas of Pinkus, 11 basal cell carcinomas, 12 trichoepitheliomas, and 3 trichoblastomas.
  • Androgen receptor expression was present in 77% (10/13) of fibroepitheliomas of Pinkus, 73% (8/11) of basal cell carcinomas, 17% (2/12) of trichoepitheliomas, and 0% (0/3) of trichoblastomas.
  • Androgen receptor expression was significantly higher in fibroepitheliomas of Pinkus compared with trichoepitheliomas and trichoblastomas (P = .0007), but not basal cell carcinoma (P = 1.00).
  • Tumor-associated Merkel cells, a feature of benign follicular tumors, was identified by cytokeratin 20 stains.
  • Merkel cells were identified in 85% (11/13) of fibroepitheliomas of Pinkus, 27% (3/11) of basal cell carcinoma cases, and 73% (11/15) of benign follicular tumors.
  • Cytokeratin 20 expression was significantly higher in fibroepithelioma of Pinkus and benign follicular tumors compared with basal cell carcinomas (P = 0.0111 and P = 0.025, respectively).
  • Similar to basal cell carcinomas, fibroepitheliomas of Pinkus express androgen receptors, potentially supporting classification as a basal cell carcinoma.
  • Conversely, fibroepithelioma of Pinkus demonstrates retention of Merkel cells, a feature of benign follicular tumors.
  • [MeSH-major] Carcinoma, Basal Cell / classification. Carcinoma, Basal Cell / metabolism. Neoplasms, Fibroepithelial / classification. Neoplasms, Fibroepithelial / metabolism. Receptors, Androgen / metabolism. Skin Neoplasms / classification. Skin Neoplasms / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Biopsy. DNA, Neoplasm / genetics. Gene Expression Regulation, Neoplastic. Genetic Variation / genetics. Hair Follicle / metabolism. Hair Follicle / pathology. Humans. Keratin-20 / genetics. Keratin-20 / metabolism. Merkel Cells / metabolism. Merkel Cells / pathology. Skin / metabolism. Skin / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Dermatopathol. 2007 Oct;29(5):494 [17890926.001]
  • (PMID = 17284955.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Keratin-20; 0 / Receptors, Androgen
  •  go-up   go-down


25. Wang Y, Revelo MP, Sudilovsky D, Cao M, Chen WG, Goetz L, Xue H, Sadar M, Shappell SB, Cunha GR, Hayward SW: Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. Prostate; 2005 Jul 1;64(2):149-59
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development and characterization of efficient xenograft models for benign and malignant human prostate tissue.
  • METHODS: This paper describes methods for xenografting both benign and malignant human prostate tissue to severe combined immunodeficient (SCID) mice.
  • RESULTS: Sub-renal capsule grafting was most efficient in terms of take rate (>90%) for both benign and malignant tissue.
  • Grafted benign tissues in all sites appropriately expressed AR, PSA, cytokeratins 8, 18, and 14 as well as p63; carcinoma tissues did not express the basal cell markers.
  • [MeSH-major] Neoplasm Transplantation. Prostate / pathology. Prostatic Hyperplasia / pathology. Prostatic Neoplasms / pathology. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • [CommentIn] Asian J Androl. 2014 May-Jun;16(3):407-12 [24589467.001]
  • (PMID = 15678503.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA89520; United States / NCI NIH HHS / CA / CA96403; United States / NIDDK NIH HHS / DK / DK063587; United States / NCI NIH HHS / CA / P30 CA68485
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


26. Ali F, Brown A, Gottwald L, Thomas J: Basal cell carcinoma with matrical differentiation in a transplant patient: a case report and review of the literature. J Cutan Pathol; 2005 Jul;32(6):445-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma with matrical differentiation in a transplant patient: a case report and review of the literature.
  • BACKGROUND: Shadow cells, characterized by basaloid squamous cells with a distinct well-defined border and a central unstained area as a shadow of lost nuclei, are characteristic of pilomatricoma, a distinct neoplasm of hair matrix differentiation.
  • The presence of shadow cells within tumor islands composed of follicular germinative cells of an otherwise classic basal cell carcinoma (BCC) has been considered as a distinct diagnostic category of BCC with matrical differentiation.
  • In these areas, the tumor nodules were connected to the epidermis, whereas in others, it extended deep into the reticular dermis to the subcutaneous fat junction.
  • Elsewhere, the majority of the tumor contained a population of shadow cells, similar to those in pilomatricoma, with basaloid-appearing matrical cells in the periphery.
  • Areas of cystic degeneration were present throughout the tumor.
  • CONCLUSION: BCC with matrical differentiation is a distinct pathologic entity and a rare subtype of BCC featuring shadow and matrical cells, typically seen in pilomatricoma, a benign hair matrix neoplasm.
  • This tumor has not yet been reported in an immunosuppressed transplant patient.
  • [MeSH-major] Carcinoma, Basal Cell / immunology. Carcinoma, Basal Cell / pathology. Heart Transplantation. Immunocompromised Host. Skin Neoplasms / immunology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Heart Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15953381.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


27. Hagemann T, Binder C, Binder L, Pukrop T, Trümper L, Grimshaw MJ: Expression of endothelins and their receptors promotes an invasive phenotype of breast tumor cells but is insufficient to induce invasion in benign cells. DNA Cell Biol; 2005 Nov;24(11):766-76
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of endothelins and their receptors promotes an invasive phenotype of breast tumor cells but is insufficient to induce invasion in benign cells.
  • There is increased staining of endothelins (ET-1, -2, and -3) and receptors (ET-RA and -RB) in invasive breast tumors compared to nonneoplastic tissue, and ETs stimulate MCF-7 cell invasion in vitro.
  • We analyzed ETstimulation of benign and transformed mammary epithelial cells, and whether expression of ETs is sufficient to induce invasiveness.
  • In breast cancer patient serum, ET-1 was increased in those patients with lymph node metastases compared to those with no lymph node involvement; ETs, however, had no mitogenic effect on breast tumor cell lines in vitro.
  • The benign mammary epithelial cell line, hTERT-HME1, and the poorly invasive breast tumor cell line MCF-7 secreted low levels of ET-1, while the invasive cell lines SKBR3 and MDAMB231 secreted high levels.
  • Expression of the ETs and receptors by the cell lines broadly correlated with their in vitro invasiveness; overexpression of ETs in MCF-7 cells increased basal invasion.
  • In contrast to transformed cells, ET stimulation or overexpression did not induce an invasive phenotype in benign cells.
  • Benign cells do not respond to ETs, and ET expression is not sufficient to induce invasion; however, the level of ET production by tumor cells correlates with their invasiveness, and increasing expression of the ET axis promotes breast tumor cell invasion via both receptors, while MMP-14 is induced via ET-RA.
  • [MeSH-minor] Calcium / metabolism. Cell Line. Cell Line, Tumor. Endothelin-1 / blood. Endothelin-1 / metabolism. Enzyme Induction. Female. Humans. Lymphatic Metastasis. Mammary Glands, Human / metabolism. Mammary Glands, Human / pathology. Matrix Metalloproteinases / biosynthesis. Neoplasm Invasiveness. Phenotype. Signal Transduction

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16274297.001).
  • [ISSN] 1044-5498
  • [Journal-full-title] DNA and cell biology
  • [ISO-abbreviation] DNA Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Endothelin-1; 0 / Endothelins; 0 / Receptor, Endothelin A; 0 / Receptor, Endothelin B; EC 3.4.24.- / Matrix Metalloproteinases; SY7Q814VUP / Calcium
  •  go-up   go-down


28. Sakamoto K, Ono T, Nakamura Y, Harada H, Nakashima T: Expression of cluster of differentiation 9 glycoprotein in benign and malignant parotid gland tumours. J Laryngol Otol Suppl; 2009;(31):58-63

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cluster of differentiation 9 glycoprotein in benign and malignant parotid gland tumours.
  • Regarding benign parotid gland tumours, cluster of differentiation 9 glycoprotein was present in 13 of 18 pleomorphic adenomas, in all Warthin tumours tested (21/21) and in all cases of basal cell adenoma tested (four of four).
  • Cluster of differentiation 9 glycoprotein was present in 11 of 14 mucoepidermoid carcinomas, in two of five acinic cell carcinomas and in two of five adenoid cystic carcinomas.
  • CONCLUSIONS: There was a statistically significantly reduced expression of cluster of differentiation 9 glycoprotein in malignant parotid gland tumours, compared with benign parotid gland tumours (p < 0.05).
  • [MeSH-major] Antigens, CD / analysis. Membrane Glycoproteins / analysis. Neoplasm Proteins / analysis. Parotid Gland / chemistry. Parotid Neoplasms / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19460206.001).
  • [ISSN] 0144-2945
  • [Journal-full-title] The Journal of laryngology and otology. Supplement
  • [ISO-abbreviation] J Laryngol Otol Suppl
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD9; 0 / CD9 protein, human; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins
  •  go-up   go-down


29. Peschos D, Damala C, Stefanou D, Tsanou E, Assimakopoulos D, Vougiouklakis T, Charalabopoulos K, Agnantis NJ: Expression of matrix metalloproteinase-9 (gelatinase B) in benign, premalignant and malignant laryngeal lesions. Histol Histopathol; 2006 06;21(6):603-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of matrix metalloproteinase-9 (gelatinase B) in benign, premalignant and malignant laryngeal lesions.
  • They are involved in basement membrane disruption, stroma and blood vessel penetration, metastasis and more recently there is evidence that they participate in tumor growth and angiogenic events.
  • Matrix metalloproteinase 2 and 9 (MMP 2 and 9) belong to the gelatinases, a subgroup of MMPs, and have the capacity to degrade the triple helix type IV collagen of basal lamina of the basement membrane.
  • With the present study, we tried to demonstrate the expression of MMP-9 immunohistochemically, comparatively in benign, premalignant and malignant lesions of the larynx.
  • We studied 154 laryngeal lesions including 55 squamous cell carcinomas, 8 in situ carcinomas, 54 cases of dysplasia (of low and intermediate grade), 13 papillomas and 24 cases of keratosis.
  • Overexpression of MMP 9 was observed in 74.4% and 50% in invasive and in situ squamous cell carcinomas respectively.
  • In dysplastic cases, in papillomas and in keratoses the percentage of overexpression was 62.9%, 61.53% and 54.16% respectively and the expression of MMP-9 was significantly higher in invasive squamous cell carcinomas compared to dysplasias (p=0.000004).
  • The MMP-9 expression was related neither to survival nor to the other available clinicopathological parameters (tumor size, grade, clinical stage, lymph node status and patient age).
  • [MeSH-minor] Carcinoma in Situ / chemistry. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Squamous Cell / chemistry. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Disease Progression. Female. Humans. Immunohistochemistry. Keratosis / metabolism. Keratosis / pathology. Laryngeal Diseases / metabolism. Laryngeal Diseases / pathology. Male. Middle Aged. Neoplasm Invasiveness / pathology. Papilloma / chemistry. Papilloma / metabolism. Papilloma / pathology. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16528670.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


30. Huss WJ, Gray DR, Greenberg NM, Mohler JL, Smith GJ: Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells. Cancer Res; 2005 Aug 1;65(15):6640-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells.
  • Putative prostate stem cells and prostate tumor stem cells in benign and malignant human prostate tissue, in primary human prostate xenografts, and in the transgenic adenocarcinoma of the mouse prostate (TRAMP) mouse model of prostate cancer, are defined by expression of breast cancer resistance protein (BCRP), a marker of pluripotent hematopoietic, muscle, and neural stem cells, and by an absence of androgen receptor (AR) protein.
  • Inhibition of BCRP-mediated efflux of dihydrotestosterone by novobiocin or fumitremorgin C in a rat prostate progenitor cell line that expresses BCRP and AR mRNAs, but minimal AR protein, results in stabilization and nuclear translocation of AR protein, providing a mechanism for lack of AR protein in BCRP-expressing stem cells.
  • In both benign and malignant human prostate tissue, the rare epithelial cells that express BCRP and lack AR protein are localized in the basal cell compartment, survive androgen deprivation, and maintain proliferative potential in the hypoxic, androgen-deprived prostate.
  • Putative prostate tumor stem cells that express BCRP but not AR protein in TRAMP are the source of a BCRP-negative and AR-negative, Foxa2- and SV40Tag-expressing, transit amplifying compartment that progresses to the poorly differentiated carcinomas that arise rapidly after castration.
  • Therefore, BCRP expression isolates prostate stem/tumor stem cells from the prostate tissue microenvironment through constitutive efflux of androgen, protecting the putative tumor stem cells from androgen deprivation, hypoxia, or adjuvant chemotherapy, and providing the nidus for recurrent prostate cancer.

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NOVOBIOCIN .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16061644.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA84296; United States / NCI NIH HHS / CA / P01 CA077739; United States / NCI NIH HHS / CA / CA77739; United States / NCI NIH HHS / CA / CA64851; United States / NIEHS NIH HHS / ES / ES07017; United States / NCI NIH HHS / CA / CA64865
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / Androgens; 0 / Indoles; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Receptors, Androgen; 17EC19951N / Novobiocin; CW5S8OP3VO / tryptoquivaline
  •  go-up   go-down


31. Kuźbicki L, Gajo B, Chwirot BW: Different expression of lysosome-associated membrane protein-1 in human melanomas and benign melanocytic lesions. Melanoma Res; 2006 Jun;16(3):235-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different expression of lysosome-associated membrane protein-1 in human melanomas and benign melanocytic lesions.
  • It is thought that enhanced expression of lysosome-associated membrane protein-1 in tumour cells may promote invasion by influencing both adhesion to extracellular matrix and perhaps also binding to endothelial cells.
  • The present study was aimed at examining levels of lysosome-associated membrane protein-1 in human melanomas and benign pigmented lesions to evaluate whether this protein might be considered a potential molecular marker of melanoma progression.
  • The expression of lysosome-associated membrane protein-1 was for the first time determined immunohistochemically in formalin-fixed paraffin-embedded specimens comprising 42 primary cutaneous melanomas, 15 lymph node melanoma metastases (11 correlated with primary tumours), three melanoma recurrences (correlated with both primary and metastatic melanomas), 27 nevi and four epithelial tumours (two seborrhoeic keratoses and two basal cell carcinomas).
  • [MeSH-minor] Epithelial Cells / metabolism. Epithelial Cells / pathology. Humans. Immunohistochemistry. Lymphatic Metastasis. Neoplasm Recurrence, Local / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16718270.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Lysosomal-Associated Membrane Protein 1
  •  go-up   go-down


32. Reis-Filho JS, Steele D, Di Palma S, Jones RL, Savage K, James M, Milanezi F, Schmitt FC, Ashworth A: Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue. Mod Pathol; 2006 Feb;19(2):307-19
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue.
  • NGFR is reported to act as a tumour suppressor, negatively regulating cell growth and proliferation.
  • NGFR expression was immunohistochemically analysed in normal breast tissue and in 140 benign, biphasic and preinvasive breast lesions, in 22 tumours with myoepithelial differentiation and in two cohorts of breast cancer patients: a series of 245 invasive breast carcinomas studied with tissue microarrays and 37 high-grade invasive ductal carcinomas with basal-like immunophenotype.
  • Myoepithelial cells of benign proliferations and pre-invasive lesions were consistently positive for NGFR.
  • Positivity for NGFR was observed in 11 out of 245 (4.5%) breast carcinomas, nine out of 20 (45%) metaplastic breast carcinomas and 14 out of 37 (38%) basal-like breast carcinomas.
  • NGFR showed a statistically significant association with longer disease-free (P<0.05) and overall survival (P<0.01) in the cohort of patients with basal-like carcinomas.
  • Furthermore, provisional data in a small number of basal-like breast carcinomas suggest that NGFR may identify a subgroup of basal-like breast carcinomas with good prognosis.
  • [MeSH-minor] Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Epithelial Cells / chemistry. Epithelial Cells / pathology. Female. Fibroadenoma / metabolism. Fibroadenoma / pathology. Fibrocystic Breast Disease / metabolism. Fibrocystic Breast Disease / pathology. Humans. Immunohistochemistry. Keratin-14. Keratin-5. Keratin-6. Keratins / analysis. Myoepithelioma / metabolism. Myoepithelioma / pathology. Neoplasm Invasiveness. Receptors, Estrogen / analysis. Receptors, Nerve Growth Factor. Receptors, Progesterone / analysis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16424897.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRT14 protein, human; 0 / KRT5 protein, human; 0 / KRT6A protein, human; 0 / KRT6B protein, human; 0 / KRT6C protein, human; 0 / Keratin-14; 0 / Keratin-5; 0 / Keratin-6; 0 / NGFR protein, human; 0 / Nerve Tissue Proteins; 0 / Receptors, Estrogen; 0 / Receptors, Growth Factor; 0 / Receptors, Nerve Growth Factor; 0 / Receptors, Progesterone; 68238-35-7 / Keratins
  •  go-up   go-down


33. Savage K, Lambros MB, Robertson D, Jones RL, Jones C, Mackay A, James M, Hornick JL, Pereira EM, Milanezi F, Fletcher CD, Schmitt FC, Ashworth A, Reis-Filho JS: Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res; 2007 Jan 1;13(1):90-101
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis.
  • PURPOSE: The distribution and significance of caveolin 1 (CAV1) expression in different breast cell types and role in breast carcinogenesis remain poorly understood.
  • Both tumor-suppressive and oncogenic roles have been proposed for this protein.
  • The aims of this study were to characterize the distribution of CAV1 in normal breast, benign breast lesions, breast cancer precursors, and metaplastic breast carcinomas; to assess the prognostic significance of CAV1 expression in invasive breast carcinomas; and to define whether CAV1 gene amplification is the underlying genetic mechanism driving CAV1 overexpression in breast carcinomas.
  • CAV1 expression was immunohistochemically analyzed in benign lesions, breast cancer precursors, and metaplastic breast carcinomas and in a cohort of 245 invasive breast carcinomas from patients treated with surgery followed by anthracycline-based chemotherapy.
  • In the later cohort, CAV1 expression was significantly associated with 'basal-like' immunophenotype and with shorter disease-free and overall survival on univariate analysis.
  • CONCLUSIONS: The concurrent CAV1 amplification and overexpression call into question its tumor-suppressive effects in basal-like breast carcinomas.
  • [MeSH-minor] Cell Line, Tumor. Female. Humans. Immunophenotyping. Microscopy, Fluorescence. Microscopy, Immunoelectron. Neoplasm Invasiveness. Neoplasm Metastasis. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17200343.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Caveolin 1
  •  go-up   go-down


34. Kazakov DV, Schaller J, Vanecek T, Kacerovska D, Michal M: Brooke-Spiegler syndrome: report of a case with a novel mutation in the CYLD gene and different types of somatic mutations in benign and malignant tumors. J Cutan Pathol; 2010 Aug;37(8):886-90
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brooke-Spiegler syndrome: report of a case with a novel mutation in the CYLD gene and different types of somatic mutations in benign and malignant tumors.
  • The available histopathological material included 24 trichoepitheliomas, 2 large nodular basal cell carcinomas (BCCs), 2 spiradenomas, 1 spiradenocylindroma and 1 trichoblastoma composed of large and small nodules with prominent clear cell differentiation.
  • Whereas one of the two BCCs manifested a conventional morphology, the second neoplasm additionally showed foci with high grade cytological features characterized by marked pleomorphism and numerous mitotic figures.
  • [MeSH-major] Adenoma / genetics. Carcinoma, Adenoid Cystic / genetics. Carcinoma, Basal Cell / genetics. Carcinoma, Skin Appendage / genetics. Facial Neoplasms / genetics. Skin Neoplasms / genetics. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Brooke-Spiegler syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20132422.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / CYLD protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


35. Garnier B, Simon E, Dumont T, Sellal S, Stricker M, Chassagne JF: [Goal cell carcinoma: really a low malignancy tumor?]. Rev Stomatol Chir Maxillofac; 2005 Feb;106(1):16-21
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Goal cell carcinoma: really a low malignancy tumor?].
  • [Transliterated title] Les carcinomes cutanés basocellulaires méritent-ils leur réputation de tumeurs à faible malignité?
  • Although basal cell carcinoma often presents as a fairly "benign" lesion early in its course, it remains the most frequent malignancy worldwide.
  • We show that advanced basal cell carcinoma can be mutilating or even life threatening depending on location, type of lesion, or pre-existing co-morbidity.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Facial Neoplasms / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Humans. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15798647.001).
  • [ISSN] 0035-1768
  • [Journal-full-title] Revue de stomatologie et de chirurgie maxillo-faciale
  • [ISO-abbreviation] Rev Stomatol Chir Maxillofac
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 22
  •  go-up   go-down


36. Wright NA, Thomas CG, Calame A, Cockerell CJ: Granular cell atypical fibroxanthoma: case report and review of the literature. J Cutan Pathol; 2010 Mar;37(3):380-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular cell atypical fibroxanthoma: case report and review of the literature.
  • We present a case of granular cell atypical fibroxanthoma of the scalp.
  • The neoplasm occurred as a tender nodule on the frontal scalp of an 82-year-old Caucasian man.
  • The granular cell phenotype has been observed in other cutaneous neoplasms including granular cell tumors, dermatofibromas, dermatofibrosarcoma protuberans, fibrous papules, basal cell carcinomas, leiomyosarcomas, angiosarcomas and primitive polypoid granular cell tumors.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Histiocytoma, Benign Fibrous / pathology. Skin Neoplasms / pathology. Xanthomatosis / pathology
  • [MeSH-minor] Aged, 80 and over. Biomarkers, Tumor. Disease-Free Survival. Humans. Immunohistochemistry. Male. Scalp / metabolism. Scalp / pathology. Scalp / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19341433.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


37. Zedek DC, Langel DJ, White WL: Clear-cell acanthoma versus acanthosis: a psoriasiform reaction pattern lacking tricholemmal differentiation. Am J Dermatopathol; 2007 Aug;29(4):378-84
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear-cell acanthoma versus acanthosis: a psoriasiform reaction pattern lacking tricholemmal differentiation.
  • Clear-cell acanthoma (CCA) has been reported to be a benign epidermal neoplasm; however, several authors have suggested alternative differentiation as well as other nosologic categories, including a reactive dermatosis.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cicatrix / pathology. Dermatitis / pathology. Epidermis / pathology. Female. Hidradenitis Suppurativa / pathology. Humans. Hyperplasia. Keratins / analysis. Keratosis, Seborrheic / pathology. Male. Middle Aged. Molecular Weight. Neoplasms, Basal Cell / pathology. Nerve Tissue Proteins / analysis. Receptors, Nerve Growth Factor / analysis

  • Genetic Alliance. consumer health - Acanthoma.
  • MedlinePlus Health Information. consumer health - Psoriasis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17667172.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NGFR protein, human; 0 / Nerve Tissue Proteins; 0 / Receptors, Nerve Growth Factor; 68238-35-7 / Keratins
  •  go-up   go-down


38. Chakraborty S, Swanson BJ, Bonthu N, Batra SK: Aberrant upregulation of MUC4 mucin expression in cutaneous condyloma acuminatum and squamous cell carcinoma suggests a potential role in the diagnosis and therapy of skin diseases. J Clin Pathol; 2010 Jul;63(7):579-84
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant upregulation of MUC4 mucin expression in cutaneous condyloma acuminatum and squamous cell carcinoma suggests a potential role in the diagnosis and therapy of skin diseases.
  • METHODS: A total of 330 tissue spots representing the normal skin, and benign and malignant cutaneous diseases, were analysed after staining with the monoclonal antibody to human MUC4 (clone 8G7).
  • RESULTS: While the normal epidermis showed a negative to weak-positive expression of MUC4, its expression was significantly upregulated in squamous cell carcinomas (SCCs) where the intensity of staining correlated negatively with tumour grade and positively with age.
  • Malignant melanoma, basal cell carcinoma and cutaneous cysts were negative.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Genital Warts.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 2000 Jan;42(1 Pt 2):4-7 [10607349.001]
  • [Cites] Int J Gynecol Pathol. 2009 Mar;28(2):127-33 [19188823.001]
  • [Cites] Dermatol Clin. 2000 Apr;18(2):xv-xxi [10791144.001]
  • [Cites] N Engl J Med. 2001 Mar 29;344(13):975-83 [11274625.001]
  • [Cites] Microbes Infect. 2002 Sep;4(11):1121-4 [12361911.001]
  • [Cites] Pancreas. 2003 Apr;26(3):e48-54 [12657964.001]
  • [Cites] J Histochem Cytochem. 2004 Feb;52(2):253-61 [14729877.001]
  • [Cites] Hepatology. 2004 Jan;39(1):220-9 [14752841.001]
  • [Cites] Histopathology. 1984 May;8(3):423-34 [6329942.001]
  • [Cites] Am J Surg Pathol. 2005 Jun;29(6):806-13 [15897748.001]
  • [Cites] Prostate. 2006 Mar 1;66(4):421-9 [16302265.001]
  • [Cites] Dig Dis Sci. 2006 Feb;51(2):381-9 [16534686.001]
  • [Cites] J Dermatol. 2006 May;33(5):309-18 [16700662.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4257-64 [16857800.001]
  • [Cites] Mod Pathol. 2006 Oct;19(10):1386-94 [16880776.001]
  • [Cites] Lung Cancer. 2007 Feb;55(2):195-203 [17126950.001]
  • [Cites] Arch Pathol Lab Med. 2007 Apr;131(4):556-62 [17425384.001]
  • [Cites] Mol Cancer Res. 2007 Apr;5(4):309-20 [17406026.001]
  • [Cites] FASEB J. 2008 Apr;22(4):966-81 [18024835.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2065-70 [18381409.001]
  • [Cites] Br J Cancer. 2008 May 6;98(9):1540-7 [18392050.001]
  • [Cites] Br J Cancer. 2008 Aug 5;99(3):520-6 [18665193.001]
  • [Cites] Br J Cancer. 2008 Sep 16;99(6):949-56 [18781152.001]
  • [Cites] J Biosci. 2009 Mar;34(1):113-23 [19430123.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2000 Jan;41(1):82-8 [10634605.001]
  • (PMID = 20591909.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA078590-13; United States / NCI NIH HHS / CA / U01 CA111294; United States / NCI NIH HHS / CA / R01 CA78590; United States / NCI NIH HHS / CA / P50 CA127297; United States / NCI NIH HHS / CA / R01 CA078590; United States / NCI NIH HHS / CA / R01 CA131944; United States / NCI NIH HHS / CA / R01 CA 133774; United States / NCI NIH HHS / CA / R01 CA133774
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC4 protein, human; 0 / Mucin-4; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ NIHMS224552; NLM/ PMC2920126
  •  go-up   go-down


39. Patel AB, Harting MS, Smith-Zagone MJ, Hsu S: Familial basaloid follicular hamartoma: a report of one family. Dermatol Online J; 2008;14(4):14
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Basaloid follicular hamartoma is a rare but benign adnexal neoplasm that can simulate basal cell carcinoma.
  • Criteria for distinction between the hamartoma and carcinoma are delineated, although evolution of basaloid follicular hamartoma into basal cell carcinoma may also be a possibility.
  • [MeSH-major] Hamartoma / diagnosis. Neoplasms, Basal Cell / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Diagnosis, Differential. Female. Humans. Male. Receptors, Cell Surface / genetics. Skin / pathology

  • Genetic Alliance. consumer health - Basaloid Follicular Hamartoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18627736.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Cell Surface; 0 / patched receptors
  •  go-up   go-down


40. Marioni G, Pillon M, Bertolin A, Staffieri A, Marino F: The role of survivin expression in the differential diagnosis of laryngeal (glottic) verrucous squamous cell carcinoma. Eur J Surg Oncol; 2007 Mar;33(2):229-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of survivin expression in the differential diagnosis of laryngeal (glottic) verrucous squamous cell carcinoma.
  • AIMS: Laryngeal verrucous squamous cell carcinoma (VSCC) is a highly differentiated carcinoma (SCC) whose histological diagnosis has many pitfalls in particular considering small biopsies: multiple glottic biopsies may be necessary to conclude for a malignant or benign lesion (papillary hyperplasia).
  • Mean survivin expressions in the VSCC basal layer, hyper-proliferative areas of laryngeal papillary hyperplasia, and SCC were 62.7%, 68.3%, and 70.0%, respectively.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Carcinoma, Verrucous / pathology. Glottis / pathology. Laryngeal Neoplasms / pathology. Microtubule-Associated Proteins / biosynthesis. Neoplasm Proteins / biosynthesis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17088041.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


41. de Koning HD, Bovenschen HJ: Two adjacent nodules on the leg. Dermatol Online J; 2010;16(6):13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Poroma is a rare benign neoplasm (derived from the intraepidermal part of the eccrine or apocrine duct), which may clinically mimic malignant tumors such as (amelanotic) malignant melanoma and porocarcinoma.
  • Histopathological examination is the key to the correct diagnosis, which is illustrated in the present case, in which a pigmented basal cell carcinoma and a poroma are in close proximity to each other.
  • Despite a clinical differential diagnosis of melanoma, histopathology showed the typical characteristics of a poroma, a rare but much more favorable tumor.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Leg. Poroma / diagnosis. Sweat Gland Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20579468.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Dos Santos JN, Oliveira GQ, Gurgel CA, de Souza RO, Sales CB, de Aguiar Pires Valença Neto A, Ramos EA: Altered expression of cytokeratins in primary, recurrent and syndrome keratocystic odontogenic tumors. J Mol Histol; 2009 Aug;40(4):269-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Keratocystic odontogenic tumor (KOT) is a benign cystic tumor that affects the jaw bones and may be associated with the nevoid basal cell carcinoma syndrome (NBCCS).
  • CK14 was expressed in all epithelial layers and in those areas where inflammation and subepithelial splits were present; this protein was preserved within the basal cells.
  • CK 18 was expressed mainly in the basal layer, whereas CK19 was expressed mainly on the intermediate and superficial layers.
  • [MeSH-major] Basal Cell Nevus Syndrome / pathology. Jaw Neoplasms / pathology. Keratins / biosynthesis. Neoplasm Recurrence, Local / pathology. Odontogenic Cysts / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 May;99(5):527-8 [15829870.001]
  • [Cites] J Oral Maxillofac Surg. 2000 Aug;58(8):862-5; discussion 866 [10935585.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Mar;91(3):328-33 [11250631.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 Apr;107(4):e43-6 [19201226.001]
  • [Cites] J Oral Pathol Med. 1989 Feb;18(2):63-7 [2473204.001]
  • [Cites] Oral Oncol. 2004 May;40(5):545-51 [15006629.001]
  • [Cites] J Invest Dermatol. 2004 Nov;123(5):x-xi [15482464.001]
  • [Cites] J Oral Sci. 2008 Mar;50(1):15-8 [18403878.001]
  • [Cites] Br J Dermatol. 1999 Aug;141(2):231-9 [10468793.001]
  • [Cites] J Oral Pathol. 1987 Aug;16(7):338-46 [2444682.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 1999 Jul;45(5):567-78 [10512189.001]
  • [Cites] J Int Med Res. 2002 Mar-Apr;30(2):131-6 [12025520.001]
  • [Cites] J Cutan Pathol. 2003 Apr;30(4):237-41 [12680953.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Dec;94(6):732-7 [12464899.001]
  • [Cites] J Oral Sci. 2008 Jun;50(2):205-12 [18587212.001]
  • [Cites] J Oral Pathol Med. 2005 Oct;34(9):558-64 [16138895.001]
  • [Cites] Subcell Biochem. 1998;31:205-62 [9932494.001]
  • [Cites] J Periodontal Res. 1993 Jan;28(1):49-59 [7678864.001]
  • [Cites] Int J Oral Maxillofac Surg. 2004 Jul;33(5):458-62 [15183409.001]
  • [Cites] Laryngoscope. 2000 Aug;110(8):1328-32 [10942135.001]
  • [Cites] Exp Mol Pathol. 2006 Aug;81(1):72-6 [16445908.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2006 Sep;14(3):303-8 [16932021.001]
  • [Cites] J Biol Chem. 2007 Mar 16;282(11):8219-27 [17213200.001]
  • [Cites] J Oral Sci. 2006 Jun;48(2):59-62 [16858133.001]
  • [Cites] Med Oral Patol Oral Cir Bucal. 2007 Mar 01;12(2):E85-91 [17322811.001]
  • [Cites] Histopathology. 2002 May;40(5):403-39 [12010363.001]
  • [Cites] Histochem Cell Biol. 2008 Jun;129(6):705-33 [18461349.001]
  • [Cites] Cytopathology. 2007 Dec;18(6):361-6 [17388930.001]
  • [Cites] Int J Oral Maxillofac Surg. 1996 Apr;25(2):124-9 [8727585.001]
  • [Cites] J Oral Pathol Med. 2006 Feb;35(2):75-80 [16430736.001]
  • [Cites] Lab Invest. 1985 Mar;52(3):243-56 [2579289.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1987 Oct;64(4):439-44 [2443892.001]
  • [Cites] J Oral Maxillofac Surg. 2000 Sep;58(9):935-40; discussion 940-1 [10981972.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Dec;4(8):871-6 [8634660.001]
  • [Cites] Clin Biochem. 2004 Jul;37(7):529-40 [15234234.001]
  • [Cites] J Pathol. 1988 Dec;156(4):283-90 [2465398.001]
  • [Cites] Cell. 1982 Nov;31(1):11-24 [6186379.001]
  • [Cites] J Mol Histol. 2008 Jun;39(3):311-6 [18256893.001]
  • [Cites] Oncol Rep. 2007 Sep;18(3):639-43 [17671713.001]
  • [Cites] Oral Dis. 2003 Jan;9(1):1-6 [12617250.001]
  • (PMID = 19915949.001).
  • [ISSN] 1567-2387
  • [Journal-full-title] Journal of molecular histology
  • [ISO-abbreviation] J. Mol. Histol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


43. Diniz MG, Borges ER, Guimarães AL, Moreira PR, Brito JA, Gomez MV, De Marco L, Gomez RS: PTCH1 isoforms in odontogenic keratocysts. Oral Oncol; 2009 Mar;45(3):291-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Odontogenic keratocyst (OKC) is an aggressive benign odontogenic neoplasm associated with PTCH1 alteration.
  • Forty OKC, including 12 sporadic and 28 associated with Nevoid Basal Cell Carcinoma Syndrome (NBCCS), were included in the study.
  • In addition, the pattern of exon 1 expression observed in oral mucosa adjacent to the OKC was similar to the OKC tumor.
  • [MeSH-major] Odontogenic Cysts / metabolism. Receptors, Cell Surface / metabolism
  • [MeSH-minor] Adolescent. Adult. Basal Cell Nevus Syndrome / genetics. Basal Cell Nevus Syndrome / metabolism. Exons / genetics. Female. Humans. Male. Middle Aged. Mouth Mucosa / metabolism. Protein Isoforms / genetics. Protein Isoforms / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18674957.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / Receptors, Cell Surface; 0 / patched receptors
  •  go-up   go-down


44. Merritt BG, Snow SN, Longley BJ: Desmoplastic trichoepithelioma, infiltrative/morpheaform BCC, and microcystic adnexal carcinoma: differentiation by immunohistochemistry and determining the need for Mohs micrographic surgery. Cutis; 2010 May;85(5):254-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Desmoplastic trichoepithelioma (DTE), infiltrative/morpheaform basal cell carcinoma (BCC), and microcystic adnexal carcinoma (MAC) are tumors in this category that may be difficult to differentiate, especially when evaluating thin biopsy specimens.
  • While DTE is a benign neoplasm with indolent behavior, infiltrative/morpheaform BCC and MAC can be highly aggressive, leading to substantial local destruction and potential metastasis.
  • We present a patient with an unusual tumor demonstrating basaloid cells in the dermis and discuss the diagnostic approach for these lesions, emphasizing the potential role of cytokeratin 20 (CK20) in determining the need for Mohs micrographic surgery.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Skin Appendage / pathology. Mohs Surgery. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Microcystic adnexal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20540416.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Keratin-20
  •  go-up   go-down


45. Pornpanich K, Chindasub P: Eyelid tumors in Siriraj Hospital from 2000-2004. J Med Assoc Thai; 2005 Nov;88 Suppl 9:S11-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: There were 53 (17.8%) inflammatory conditions, 212 (71.4%) benign eyelid tumors and 32 (10.8%) malignant eyelid tumors.
  • These 32 malignant eyelid tumors included 13 sebaceous gland carcinomas, 12 basal cell carcinomas, 3 malignant melanomas, 2 squamous cell carcinomas, 1 apocrine adenocarcinoma and 1 metastatic carcinoma.
  • CONCLUSION: The majority of eyelid lesions were benign eyelid tumors while malignant eyelid tumors contributed 10.8% of the total eyelid lesions.
  • Sebaceous gland carcinoma was the most common eyelid tumor found in their present study that was consistent with other studies from Asian countries.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Eyelid Neoplasms / epidemiology. Sebaceous Gland Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Biopsy, Needle. Child. Child, Preschool. Female. Humans. Immunohistochemistry. Incidence. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Assessment. Sex Distribution. Thailand / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681045.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


46. Livaoğlu M, Karacal N, Bektaş D, Bahadir O: Reconstruction of full-thickness nasal defect by free anterolateral thigh flap. Acta Otolaryngol; 2009 May;129(5):541-4
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All defects resulted from tumor resections.
  • Four patients had a basal cell carcinoma, one an epidermoid carcinoma, and the other patient had recurrent malignant fibrous histiocytoma.
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Female. Histiocytoma, Benign Fibrous / surgery. Humans. Length of Stay. Male. Middle Aged. Neoplasm Recurrence, Local / surgery. Thigh / surgery

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18607893.001).
  • [ISSN] 1651-2251
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


47. Smith JH, Padnick-Silver L, Newlin A, Rhodes K, Rubinstein WS: Genetic study of familial uveal melanoma: association of uveal and cutaneous melanoma with cutaneous and ocular nevi. Ophthalmology; 2007 Apr;114(4):774-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MAIN OUTCOME MEASURES: Cutaneous and ocular nevi, benign and malignant neoplasms of skin and other sites, brief skin cancer risk assessment tool risk classification for cutaneous melanoma, DNA sequencing of p16INK4a and p14ARF genes, and citations on familial uveal melanoma.
  • RESULTS: The proband and his mother had uveal melanoma, 3 cutaneous melanomas occurred among 2 siblings, and 2 other siblings had basal cell carcinomas.
  • No germline mutations were detected in the melanoma-associated tumor suppressor genes p16INK4a and p14ARF.
  • Of the 3 subjects without nevi, 2 had histories of eye or skin malignancies (1 uveal melanoma, 1 basal cell carcinoma).
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Melanoma / genetics. Nevus, Pigmented / genetics. Skin Neoplasms / genetics. Uveal Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cyclin-Dependent Kinase Inhibitor p16 / genetics. DNA, Neoplasm / analysis. Female. Humans. Male. Middle Aged. Pedigree. Risk Factors. Sequence Analysis, DNA. Surveys and Questionnaires. Tumor Suppressor Protein p14ARF / genetics

  • Genetic Alliance. consumer health - Melanoma, familial.
  • Genetic Alliance. consumer health - Ocular melanoma.
  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17207529.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Neoplasm; 0 / Tumor Suppressor Protein p14ARF
  •  go-up   go-down


48. Wang Y, Yang J, Gao Y, Zhao XL, Li HZ, Yao Z: [Relationship between raf kinase inhibitor protein and metastasis of ovarian carcinoma]. Zhonghua Fu Chan Ke Za Zhi; 2009 Jul;44(7):522-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Immunohistochemistry, RT-PCR, and western blot analysis were performed to examine the expression of RKIP in clinical samples of ovarian tumors and five human ovarian carcinoma cell lines.
  • Stable cell lines over-expressed or deleted of RKIP were cloned to investigate the function of RKIP in ovarian cancer cells.
  • The recombinant plasmids expressing sense (ss) or antisense (as) RKIP cDNA or empty vector was transfected into ovarian cancer cell line SKOV3 by lipofectamine.
  • Assays of cell proliferation, soft-agar colony formation, cell adhesion, and cell invasion in vitro were used to examine the malignant phenotypes of the transfected cells.
  • Flow cytometric analysis was performed to observe the effect of RKIP on cell cycle distribution before and after transfection. RESULTS:.
  • (1) The expression levels of RKIP protein in ovarian carcinoma tissues from patients were found to be reduced than those in ovarian benign tumor and borderline tumor.
  • SKOV3 clones stably expressing full-length recombinant ssRKIP, asRKIP, and their respective empty vector were obtained. (2) RKIP was able to block basal levels of MEK and ERK in ovarian cancer cells.
  • 48 and 0.46. (3) Abilities of cell proliferation in the ssRKIP vector-transfected cells were decreased compared with that in the non-transfected cells (P < 0.01). (4)Anchorage-independent growth in the ssRKIP#1 and ssRKIP#4 cells (83.7 +/- 5.7, 106.0 +/- 9.2) were decreased compared with that in the empty vector-transfected cells (158.3 +/- 14.6, P < 0.01). (5)Cell adhesion in the ssRKIP#1 and ssRKIP#4 cells [(68.3 +/- 0.8)%, (64.1 +/- 0.9)%] were decreased compared with that in the non-transfected cells [(100.0 +/- 1.1)%, P < 0.01]. (6) Cell invasion in the ssRKIP#1 and ssRKIP#4 cells (24 +/- 5, 25 +/- 4) were decreased compared with that in the non-transfected cells (68 +/- 5, P < 0.01). (7) ssRKIP cells had a significant increase in the G1 phase and decrease in the G2 + S phase.
  • CONCLUSION: RKIP could inhibits the metastasis, but also the growth of ovarian cancer cells. patients were found to be reduced than those in ovarian benign tumor and borderline tumor.
  • SKOV3 clones stably expressing full-length recombinant ssRKIP, asRKIP, and their respective empty vector were obtained. (2) RKIP was able to block basal levels of MEK and ERK in ovarian cancer cells.
  • The expression level of phosphorylation MEK in ssRKIP#1 and ssRKIP#4 cells were 0.35, 0.34; while the expression level of phosphorylation ERK in ssRKIP #1 and ssRKIP #4 cells were 0.48 and 0.46. (3) Abilities of cell proliferation in the ssRKIP vector-transfected cells were decreased compared with that in the non-transfected cells (P < 0.01). (4) Anchorage-independent growth in the ssRKIP#1 and ssRKIP#4 cells (83.7 +/- 5.7, 106.0 +/- 9.2) were decreased compared with that in the empty vector-transfected cells (158.3 +/- 14.6, P < 0.01). (5) Cell adhesion in the ssRKIP#1 and ssRKIP#4 cells [(68.3 +/- 0.8)%, (64.1 +/- 0.9)%] were decreased compared with that in the non-transfected cells [(100.0 +/- 1.1)%, P < 0.01]. (6) Cell invasion in the ssRKIP#1 and ssRKIP#4 cells (24 +/- 5, 25 +/- 4) were decreased compared with that in the nontransfected cells (68 +/- 5, P < 0.01). (7) ssRKIP cells had a significant increase in the G1 phase and decrease in the G2 + S phase.
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Line, Tumor. Cell Proliferation. Female. Genes, Tumor Suppressor. Genetic Vectors. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Phosphorylation. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Transfection. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19957553.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Phosphatidylethanolamine Binding Protein; 0 / RNA, Messenger; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases
  •  go-up   go-down


49. Chaichamnan K, Satayasoontorn K, Puttanupaab S, Attainsee A: Malignant proliferating trichilemmal tumors with CD34 expression. J Med Assoc Thai; 2010 Nov;93 Suppl 6:S28-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant proliferating trichilemmal tumors (MPTT) are rare neoplasm arising from outer root sheath of hair follicle, the diagnosis of which is base essentially on histological features resulting in occasionally misdiagnosis of squamous cell carcinoma.
  • In difficult cases, however evaluation of additional parameters may be needed to differentiate benign proliferating trichilemmal tumor from MPTT or differentiate PTT and MPTT from squamous cell carcinoma.
  • For comparison, concurrent proliferating trichilemmal tumors (PTT) and trichilemmal cysts (TC) as well as well-differentiated squamous cell carcinoma (SCC) were studied.
  • The PTTs and TCs stained negative and few basal cells for p53 and Ki-67, respectively.
  • [MeSH-major] Antigens, CD34 / metabolism. Carcinoma, Squamous Cell / metabolism. Epidermal Cyst / pathology. Hair Follicle / pathology. Scalp / pathology. Skin Neoplasms / pathology. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Recurrence, Local. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21280514.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


50. Deprez M, Uffer S: Clinicopathological features of eyelid skin tumors. A retrospective study of 5504 cases and review of literature. Am J Dermatopathol; 2009 May;31(3):256-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eyelid tumors are the most common neoplasm in daily ophthalmology practice and encompass a wide variety of benign and malignant tumors.
  • Benign tumors largely predominated over malignant ones, representing 84% of cases in this series, and the 5 most frequent subtypes were squamous cell papilloma (26%), seborrheic keratosis (21%), melanocytic nevus (20%), hidrocystoma (8%), and xanthoma/xanthelasma (6%).
  • Basal cell carcinoma was the most frequent malignant tumor (86%), followed by squamous cell carcinoma (7%) and sebaceous carcinoma (3%).
  • For several tumor subtypes, there was a poor correlation between clinical and histological diagnosis, stressing the numerous pitfalls in the diagnosis of eyelid tumors.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Child. Child, Preschool. Female. Hidrocystoma / pathology. Humans. Infant. Keratosis, Seborrheic / pathology. Male. Middle Aged. Nevus, Pigmented / pathology. Papilloma / pathology. Predictive Value of Tests. Retrospective Studies. Sebaceous Gland Neoplasms / pathology. Skin Neoplasms / pathology. Sweat Gland Neoplasms / pathology. Xanthomatosis / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Eyelid Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19384066.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 32
  •  go-up   go-down


51. Kazakov DV, Kutzner H, Mukensnabl P, Michal M: Low-grade adnexal carcinoma of the skin with multidirectional (glandular, trichoblastomatous, spiradenocylindromatous) differentiation. Am J Dermatopathol; 2006 Aug;28(4):341-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The conjoint occurrence of follicular, sebaceous, or apocrine differentiations in a cutaneous adnexal neoplasm is a known event, more often encountered in benign neoplasms, whereas reports of cutaneous malignant adnexal tumors with bilineage or trilineage differentiation are few.
  • A new case of a cutaneous malignant adnexal neoplasm with multidirectional differentiation is reported here.
  • A 57-year-old woman presented with a long-standing, slowly growing, asymptomatic solitary tumor the size of a large nut in the coccygeal area, which was surgically excised.
  • Microscopically, the neoplasm was located in the dermis with focal extension into the subcutis.
  • Rare nodules resembled elements seen in a spiradenoma by containing scattered lymphocytes and globules of hyalinized eosinophilic basal membrane material.
  • Mitotic figures, including abnormal ones, were infrequent, but mild nuclear pleomorphism, nuclear crowding, and individual cell necrosis were easily appreciable in both small basaloid cells and cells with clear cytoplasm.
  • We classified this tumor as a well-differentiated adnexal carcinoma demonstrating combined follicular and apocrine differentiation.
  • [MeSH-major] Adnexal Diseases / pathology. Cell Differentiation. Skin Neoplasms / pathology
  • [MeSH-minor] Cell Shape. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16871040.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Sedghizadeh PP, Wong D, Shuler CF, Linz V, Kalmar JR, Allen CM: Multifocal calcifying epithelial odontogenic tumor. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Aug;104(2):e30-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multifocal calcifying epithelial odontogenic tumor.
  • The calcifying epithelial odontogenic tumor (CEOT), or Pindborg tumor, is a rare and benign odontogenic neoplasm that affects the jaw.
  • For example, multiple odontogenic keratocysts are the most common feature of the inherited condition known as nevoid basal cell carcinoma syndrome.
  • [MeSH-minor] Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Rare Diseases

  • Genetic Alliance. consumer health - Calcifying Epithelial Odontogenic Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17630096.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Tatiana K S C, Somers GR, Pope E, Zuker RM: Predisposing factors and outcomes of malignant skin tumors in children. Plast Reconstr Surg; 2010 Aug;126(2):508-14
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Although benign and metastatic tumors occur in children, primary malignant skin tumors are uncommon in the pediatric population.
  • Diagnosis of malignant melanoma was made in 14 patients, diagnosis of basal cell carcinoma was made in four patients, and diagnosis of squamous cell carcinoma was made in one patient.
  • Gorlin syndrome was an underlying predisposing condition in three patients with basal cell carcinoma.
  • All cases of basal cell carcinoma and squamous cell carcinoma underwent surgical resection and primary closure or skin graft.
  • In accordance with previously published data, malignant melanoma was the most frequent tumor in our study.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Sentinel Lymph Node Biopsy / methods. Skin Neoplasms / epidemiology. Skin Neoplasms / surgery. Skin Transplantation / methods
  • [MeSH-minor] Adolescent. Age Distribution. Canada / epidemiology. Carcinoma, Basal Cell / epidemiology. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Causality. Child. Child, Preschool. Cohort Studies. Databases, Factual. Dermatology / methods. Female. Follow-Up Studies. Humans. Immunohistochemistry. Incidence. Male. Melanoma / epidemiology. Melanoma / pathology. Melanoma / surgery. Neoplasm Staging. Sex Distribution. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20375763.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. De Gabory L, Deminière C, Stoll D: [Immunohistochemistry expression of 3 markers (CEA, UEA-I and Ki-67) in nasal inverted papillomas]. Rev Laryngol Otol Rhinol (Bord); 2008;129(3):159-65
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Expression immunohistochimique de l'ACE, de l'UEA-I et du Ki-67 dans les papillomes inversés naso-sinusiens.
  • OBJECTIVES: Immunohistochemistry evaluation of the expression of degeneration and proliferation markers of the benign form of Schneiderian inverted papillomas in the ORL sphere, in the nondysplastic, dysplastic and degenerated forms.
  • MATERIALS AND METHOD: 44 surgical specimens were analyzed in two groups: A= 33 benign and B= 11 degenerated.
  • A simultaneous bipolar localization belonged to the two groups (nasal, benign and otologic malignant).
  • But, no difference existed between groups A and B, the various sub-groups and the benign specific localizations.
  • This expression was present in the basal cells.
  • However the expression of Ki-67 in more than 50% of the cells involving the full epithelium thickness would seem to suggest a particular cellular behavior Whereas the expression of the protein remains generally confined to the basal and suprabasal layers, a more significant population of Ki-67+ cells disseminated in the epithelium, would signify a tendency of the epithelium to escape the regulation mechanisms.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoembryonic Antigen / analysis. Ki-67 Antigen / analysis. Nose Neoplasms / pathology. Papilloma, Inverted / pathology. Paranasal Sinus Neoplasms / pathology. Plant Lectins / analysis. Sphenoid Sinus / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Child. Diagnosis, Differential. Ear Neoplasms / pathology. Ear Neoplasms / surgery. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Nasal Mucosa / pathology. Nasal Polyps / pathology. Nasal Polyps / surgery. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / surgery. Prognosis. Reference Values

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19694158.001).
  • [ISSN] 0035-1334
  • [Journal-full-title] Revue de laryngologie - otologie - rhinologie
  • [ISO-abbreviation] Rev Laryngol Otol Rhinol (Bord)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Ki-67 Antigen; 0 / Plant Lectins; 0 / Ulex europaeus lectins
  •  go-up   go-down


55. Pacchioni D, Volante M, Casetta G, Sapino A, Marchiò C, Bussolati G: Myxoid renal tumor with myoepithelial differentiation mimicking a salivary gland pleomorphic adenoma: description of a case. Am J Surg Pathol; 2007 Apr;31(4):632-6
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myxoid renal tumor with myoepithelial differentiation mimicking a salivary gland pleomorphic adenoma: description of a case.
  • We herein report an unusual case of a low-grade myxoid renal epithelial neoplasm, with peculiar and previously unreported morphologic and immunohistochemical features.
  • These were lined by 2 different epithelial cell types, flat and elongated basal cells and cuboidal to spindle shaped eosinophilic luminal cells, with low-grade nuclear features and a few small nucleoli.
  • The immunohistochemical profile interestingly confirmed the myoepithelial differentiation of the basal epithelial layer, as demonstrated by the coexpression of several myoepithelial markers such as p63, caldesmon, calponin, smooth muscle actin, and S-100, together with epithelial markers such as low and high-molecular weight cytokeratins.
  • The tumor proved benign at follow-up.
  • A definitive classification and histogenetic interpretation of this previously unreported tumor type awaits description of further cases showing similar features which, perhaps, as it may happen, went so far unnoticed.
  • [MeSH-minor] Adenoma, Pleomorphic / pathology. Aged. Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Salivary Gland Neoplasms / pathology

  • Genetic Alliance. consumer health - Salivary gland adenoma, pleomorphic.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414112.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


56. Hofer MD, Tapia C, Browne TJ, Mirlacher M, Sauter G, Rubin MA: Comprehensive analysis of the expression of the metastasis-associated gene 1 in human neoplastic tissue. Arch Pathol Lab Med; 2006 Jul;130(7):989-96
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Both analyses show that MTA1 is ubiquitously expressed in benign and malignant tumors.
  • The highest levels of MTA1 expression were observed in diffuse B-cell lymphoma (mean staining intensity, 3.9/4), basal cell carcinomas (3.7/4), and consistently in tumors of neuroendocrine descent such as paraganglioma (3.7/4) and carcinoid tumor (3.1/4).
  • CONCLUSIONS: This study characterizes MTA1 expression for the first time across a broad spectrum of primary tumors, demonstrating expression in both benign and malignant neoplasms in addition to showing an association with neuroendocrine differentiation.
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Databases, Genetic. Humans. Immunohistochemistry. Neoplasm Invasiveness. Oligonucleotide Array Sequence Analysis. Software. Tissue Array Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16831056.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Repressor Proteins; EC 3.5.1.- / Mta1 protein, human; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


57. Kazakov DV, Zelger B, Rütten A, Vazmitel M, Spagnolo DV, Kacerovska D, Vanecek T, Grossmann P, Sima R, Grayson W, Calonje E, Koren J, Mukensnabl P, Danis D, Michal M: Morphologic diversity of malignant neoplasms arising in preexisting spiradenoma, cylindroma, and spiradenocylindroma based on the study of 24 cases, sporadic or occurring in the setting of Brooke-Spiegler syndrome. Am J Surg Pathol; 2009 May;33(5):705-19
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphologic diversity of malignant neoplasms arising in preexisting spiradenoma, cylindroma, and spiradenocylindroma based on the study of 24 cases, sporadic or occurring in the setting of Brooke-Spiegler syndrome.
  • The authors present a series of 24 malignant neoplasms arising in preexisting benign spiradenoma (20), cylindroma (2), and spiradenocylindroma (2).
  • Nineteen patients (12 females, 7 males; age range, 41 to 92 y) had a solitary neoplasm (size range, 2.2 to 17.5 cm; median 4 cm), whereas the remaining 5 (4 females, 1 male; age range, 66 to 72 y) manifested clinical features of Brooke-Spiegler syndrome (BSS), an autosomal dominantly inherited disease characterized by widespread, small, benign neoplasms on which background larger malignant lesions appeared.
  • Microscopically, all cases showed the residuum of a preexisting benign neoplasm.
  • 1) salivary gland type basal cell adenocarcinoma-like pattern, low-grade (BCAC-LG);.
  • 2) salivary gland type basal cell adenocarcinoma-like pattern, high-grade (BCAC-HG);.
  • Cases harboring a sarcomatoid carcinoma featured a malignant epithelial component composed of varying combinations of BCAC-HG, BCAC-LG, IAC-NOS, or squamous cell carcinoma, whereas the sarcomatoid component appeared as either a pleomorphic or spindle-cell sarcoma.
  • The histologic pattern of the malignant neoplasm correlated to some extent with the clinical course.
  • Given the morphologic diversity and complexity of the neoplasms in question, we propose using a more specific terminology with the precise description of the neoplasm components, rather than generic and less informative terms such as "spiradenocarcinoma" or "carcinoma ex cylindroma. "
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Australia. Carcinoma, Skin Appendage / pathology. Carcinoma, Squamous Cell / pathology. Cell Differentiation. Chromosomes, Human, Pair 16. Europe. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Metaplasia. Middle Aged. Mutation. Neoplasm Invasiveness. South Africa. Syndrome. Treatment Outcome. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Malignant cylindroma.
  • Genetic Alliance. consumer health - Brooke-Spiegler syndrome.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19194280.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CYLD protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


58. Shaker O, Youssef R: Role of apoptosis stimulus factor and its ligand in the induction of apoptosis in some ultraviolet induced diseases. Dermatol Online J; 2006;12(3):4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Fas (factor of apoptosis stimulus) is one of the death receptors belonging to the tumor necrosis factor superfamily of receptors.
  • AIM: The aim of the study was to evaluate the role of Fas and Fas-L in basal cell carcinoma (BCC) as an example of malignant neoplasm and discoid lupus erythematosus (DLE) as a benign skin disease, which are both induced by UV.
  • CONCLUSION: Over-expression of Fas-L and lack of expression of Fas by tumor cells together with other factors act in favor of BCC by helping its survival and progression.
  • [MeSH-major] Antigens, CD95 / metabolism. Carcinoma, Basal Cell / pathology. Lupus Erythematosus, Discoid / metabolism. Lupus Erythematosus, Discoid / pathology. Membrane Glycoproteins / metabolism. Skin Neoplasms / pathology. Tumor Necrosis Factors / metabolism

  • MedlinePlus Health Information. consumer health - Lupus.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16638418.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Membrane Glycoproteins; 0 / Tumor Necrosis Factors
  •  go-up   go-down


59. Biswas D, Saha S, Bera SP: Relative distribution of the tumours of ear, nose and throat in the paediatric patients. Int J Pediatr Otorhinolaryngol; 2007 May;71(5):801-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients 15 years of age or under who presented with a tumour of the otolaryngological region to the department of Otolaryngology were included in this study.
  • RESULTS: Forty-three patients of above age group with a neoplasm of the otolaryngological region were managed in our department, the incidence was 0.5%.
  • The ratio of benign to malignant lesion was 7.6:1.
  • Juvenile nasopharyngeal angiofibroma was the commonest tumour (11 cases, 26%) and embryonal rhabdomyosarcoma was the commonest malignant tumour (3 cases, 7%).
  • The commonest site of neoplasm was the nose and paranasal sinuses (13 cases, 30%).
  • CONCLUSION: A tumour in the otolaryngological site in the paediatric population is rare, the incidence being 1 in 200 new cases in the age group of 15 years or under, 12% of the tumours were malignant.
  • [MeSH-minor] Adolescent. Carcinoma, Basal Cell / epidemiology. Child. Child, Preschool. Female. Hemangioma / epidemiology. Humans. Incidence. Infant. Male. Papilloma / epidemiology. Prevalence. Prospective Studies. Rhabdomyosarcoma / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17368816.001).
  • [ISSN] 0165-5876
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


60. Celis JE, Gromov P, Cabezón T, Moreira JM, Friis E, Jirström K, Llombart-Bosch A, Timmermans-Wielenga V, Rank F, Gromova I: 15-prostaglandin dehydrogenase expression alone or in combination with ACSM1 defines a subgroup of the apocrine molecular subtype of breast carcinoma. Mol Cell Proteomics; 2008 Oct;7(10):1795-809
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Molecular profiling technologies, on the other hand, subdivide breast tumors into five subtypes, basal-like, luminal A, luminal B, normal breast tissue-like, and ERBB2-positive, that have different prognostic characteristics.
  • By comparing the protein expression profiles of apocrine macrocysts and non-malignant breast epithelial tissue we have previously reported the identification of a few proteins that are specifically expressed by benign apocrine lesions as well as by the few IACs that were available to us at the time.
  • Here we reiterate our strategy to reveal apocrine cell markers and present novel data, based on the analysis of a considerably larger number of samples, establishing that IACs correspond to a distinct molecular subtype of breast carcinomas characterized by the expression of 15-prostaglandin dehydrogenase alone or in combination with a novel form of acyl-CoA synthetase medium-chain family member 1 (ACSM1).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Cohort Studies. Disease Progression. Electrophoresis, Gel, Two-Dimensional. Female. Humans. Immunohistochemistry. Immunophenotyping. Middle Aged. Neoplasm Invasiveness. Paraffin Embedding. Phenotype. Silver Staining. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18632593.001).
  • [ISSN] 1535-9484
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.1.1.- / Hydroxyprostaglandin Dehydrogenases; EC 1.1.1.141 / 15-hydroxyprostaglandin dehydrogenase; EC 6.2.1.- / ACSM1 protein, human; EC 6.2.1.- / Coenzyme A Ligases
  •  go-up   go-down


61. Badr RE, Walts AE, Chung F, Bose S: BD ProEx C: a sensitive and specific marker of HPV-associated squamous lesions of the cervix. Am J Surg Pathol; 2008 Jun;32(6):899-906
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study aims to assess ProEx C expression patterns in benign, atypical, and dysplastic lesions of the cervix and to compare these patterns with p16 and Ki67 expression and with the presence of human papilloma virus DNA as determined by in situ hybridization.
  • ProEx C positivity was limited to the basal layers of the epithelium in 75% of benign cervices.
  • [MeSH-major] Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Carcinoma, Squamous Cell / metabolism. Cell Cycle Proteins / analysis. DNA Topoisomerases, Type II / analysis. DNA-Binding Proteins / analysis. Nuclear Proteins / analysis. Papillomavirus Infections / complications. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18425044.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


62. Ritwik P, Brannon RB: Peripheral odontogenic fibroma: a clinicopathologic study of 151 cases and review of the literature with special emphasis on recurrence. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Sep;110(3):357-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The peripheral odontogenic fibroma (POdF) is a rare benign neoplasm of odontogenic origin with limited data on recurrence.
  • RESULTS: POdF should be considered a mixed odontogenic tumor because it is composed of active odontogenic epithelial and ectomesenchymal components.
  • Budding of the basal cell layer of the surface squamous epithelium was associated with higher recurrence (P=.0186); 27 cases with recurrence which exhibited this feature.
  • [MeSH-major] Fibroma / pathology. Jaw Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Odontogenic Tumors / pathology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Child. Child, Preschool. Follow-Up Studies. Humans. Infant. Infant, Newborn. Logistic Models. Male. Middle Aged. Mixed Tumor, Malignant / pathology. Sex Distribution. Time Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20674403.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


63. Tse GM, Tan PH, Moriya T: The role of immunohistochemistry in the differential diagnosis of papillary lesions of the breast. J Clin Pathol; 2009 May;62(5):407-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Correct diagnosis is crucial but may be difficult, as many benign and malignant papillary lesions have similar appearances.
  • In intracystic papillary carcinoma, there is controversy as to the presence of a complete myoepithelial cell layer around these lesions. p63 is the marker of choice as the staining is nuclear, cross-reactivity is minimal, and sensitivity is high.
  • Basal cytokeratins (CKs) are useful to differentiate these entities; as usual hyperplasia is positive for basal CKs with a mosaic staining pattern.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Diagnosis, Differential. Female. Humans. Keratins / analysis. Neoplasm Proteins / analysis. Nerve Tissue Proteins / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19126567.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; 68238-35-7 / Keratins
  • [Number-of-references] 33
  •  go-up   go-down


64. Fischer S, Breuninger H, Metzler G, Hoffmann J: Microcystic adnexal carcinoma: an often misdiagnosed, locally aggressive growing skin tumor. J Craniofac Surg; 2005 Jan;16(1):53-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microcystic adnexal carcinoma: an often misdiagnosed, locally aggressive growing skin tumor.
  • Recently it has been proposed that MAC is an apocrine tumor.
  • In 1982, Goldstein and colleagues first reported MAC to be a distinct histologic entity characterized by a combination of keratinous cysts in the upper dermis, islands and strands of small basaloid, benign-appearing keratinocytes or squamous cells in the deeper dermis within a dense desmoplastic stroma, and areas of ductular differentiation.
  • The authors report the case of a 78-year-old woman in whom a diagnosis of MAC was made when a tumor on the right cheek recurred for the second time.
  • Previous histopathologic diagnoses were squamous cell carcinoma and desmoplastic trichoepithelioma.
  • Local recurrences of the tumor occurred, despite histographic surgery because in hematoxylin and eosin stains, small islands of the deceptively benign-appearing small basaloid cells of MAC were not recognized as tumor cells.
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell / pathology. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Neoplasms, Basal Cell / pathology

  • Genetic Alliance. consumer health - Microcystic adnexal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15699645.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Kim JE, Kim HJ, Choi JM, Lee KH, Kim TY, Cho BK, Jung JY, Chung KY, Cho D, Park HJ: The antimicrobial peptide human cationic antimicrobial protein-18/cathelicidin LL-37 as a putative growth factor for malignant melanoma. Br J Dermatol; 2010 Nov;163(5):959-67
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Human cationic antimicrobial protein-18 (hCAP-18)/LL-37 production in several cell lines including HaCaT, a chronic myelogenous leukaemia (CML) cell line and various melanoma cell lines was examined using reverse transcription-polymerase chain reaction and enzyme-linked immunosorbent assay.
  • Immunohistochemical analysis of melanoma, nonmelanoma skin cancer and precancerous and benign skin lesions was performed.
  • After adding LL-37 to a melanoma cell line, tumour cell proliferation, migration and invasion were investigated.
  • RESULTS: Human malignant melanoma cell lines overexpressed hCAP-18/LL-37 mRNA and peptide compared with HaCaT and CML cell lines.
  • Immunohistochemistry showed that the peptide was strongly expressed in malignant melanoma and moderately expressed in squamous cell carcinoma, whereas basal cell carcinoma, precancerous lesions and seborrhoeic keratosis showed no or weak expression.
  • LL-37 also stimulated melanoma cell proliferation, migration and invasion in vitro.
  • LL-37 promoted melanoma cell proliferation, migration and invasion in vitro.
  • [MeSH-major] Antimicrobial Cationic Peptides / metabolism. Melanoma / metabolism. Neoplasm Proteins / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor / metabolism. Cell Movement / physiology. Cell Proliferation. Enzyme-Linked Immunosorbent Assay. Female. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Male. Middle Aged. Neoplasm Invasiveness / pathology. Precancerous Conditions / metabolism. RNA, Messenger / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. BJD © 2010 British Association of Dermatologists.
  • (PMID = 20977442.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimicrobial Cationic Peptides; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 143108-26-3 / CAP18 lipopolysaccharide-binding protein
  •  go-up   go-down


66. Lü BJ, Zhu J, Gao L, Xie L, Xu JY, Lai MD: [Diagnostic accuracy and pitfalls in fine needle aspiration cytology of salivary glands: a study of 113 cases]. Zhonghua Bing Li Xue Za Zhi; 2005 Nov;34(11):706-10
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The FNAC diagnostic failure (2); non-neoplastic lesions (12); benign neoplasm (82) and malignant neoplasm (17).
  • Cytologically, the distinction between cellular pleomorphic adenoma, adenoid cystic carcinoma and basal cell adenoma could be difficult due to their overlapping morphologic features.
  • The three inaccurately diagnosed cases of FNAC are, as follows: reactive lymphoid hyperplasia of lymph node mistaken as non-Hodgkin lymphoma, mucoepidermoid carcinoma diagnosed as "scanty atypical cells present" and primary lymphoepithelial carcinoma mistaken as benign lymphoepithelial lesion.
  • On the basis of FNAC, 97.4% (110 /113) were correctly depicted as benign (95/96; 99.0%) or malignant (15/17; 88.2%).
  • Furthermore, 90.3% (102 /113) (specificity = 91.9%; 102/111) were accurately diagnosed, including 91.7% (88/96) benign lesions (specificity = 92.6% ; 88/95) and 82.4% (14/17) malignant tumors (specificity = 87.5%; 14/16).
  • CONCLUSIONS: FNAC is reliable in distinguishing benign and malignant salivary gland lesions.
  • [MeSH-major] Carcinoma, Mucoepidermoid / pathology. Carcinoma, Squamous Cell / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16536312.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


67. Hameed O, Humphrey PA: Immunohistochemistry in diagnostic surgical pathology of the prostate. Semin Diagn Pathol; 2005 Feb;22(1):88-104
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Basal cell markers, such as the 34betaE12 antibody and antibodies directed against cytokeratin 5 and 6 or p63, are very useful for demonstration of basal cells as their presence argues against a diagnosis of invasive prostatic carcinoma (PC).
  • However, several benign mimickers of PC, including atrophy, atypical adenomatous hyperplasia (AAH), nephrogenic adenoma, and mesonephric hyperplasia, can stain negatively with these markers, and thus, a negative basal cell marker immunostain alone does not exclude a diagnosis of benignancy.
  • Although there are examples in the literature of high grade PC that stain focally with some of the basal cell markers, these cases are usually readily diagnosed based on H&E appearances and are unlikely to be confused with these benign mimickers.
  • AMACR expression can also be identified in high grade prostatic intraepithelial neoplasia (PIN), prostatic atrophy, AAH, and benign prostatic glands, and accordingly, a diagnosis of PC should not be based solely on a positive AMACR immunostain, especially when the luminal staining is weak and/or noncircumferential.
  • The use of AMACR/basal cell antibody cocktails has been found to greatly facilitate the distinction between PC and its benign mimickers, especially when only limited tissue is available for staining.
  • AMACR positivity and negative basal cell marker reactions are useful to confirm the presence of residual PC after hormonal or radiation therapy.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / pathology. Diagnosis, Differential. Humans. Leukemia / diagnosis. Lymphoma / diagnosis. Male. Neoplasm Metastasis. Sarcoma / diagnosis. Sensitivity and Specificity. Urinary Bladder Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16512601.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 192
  •  go-up   go-down


68. Rozenchan PB, Carraro DM, Brentani H, de Carvalho Mota LD, Bastos EP, e Ferreira EN, Torres CH, Katayama ML, Roela RA, Lyra EC, Soares FA, Folgueira MA, Góes JC, Brentani MM: Reciprocal changes in gene expression profiles of cocultured breast epithelial cells and primary fibroblasts. Int J Cancer; 2009 Dec 15;125(12):2767-77
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The importance of epithelial-stroma interaction in normal breast development and tumor progression has been recognized.
  • To identify genes that were regulated by these reciprocal interactions, we cocultured a nonmalignant (MCF10A) and a breast cancer derived (MDA-MB231) basal cell lines, with fibroblasts isolated from breast benign-disease adjacent tissues (NAF) or with carcinoma-associated fibroblasts (CAF), in a transwell system.
  • In MDA-MB231 highly represented genes downregulated by CAF derived factors coded for proteins important for the specificity of vectorial transport between ER and golgi, possibly affecting cell polarity whereas the response of MCF10A comprised an induction of genes coding for stress responsive proteins, representing a prosurvival effect.
  • CAFs responded to the presence of both epithelial cells inducing genes implicated in cell proliferation.
  • Our data indicate that interactions between breast fibroblasts and basal epithelial cells resulted in alterations in the genomic profiles of both cell types which may help to clarify some aspects of this heterotypic signaling.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. Epithelial Cells / metabolism. Fibroblasts / metabolism. Gene Expression Profiling. Neoplasm Proteins / genetics
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Blotting, Western. Breast / cytology. Cell Proliferation. Coculture Techniques. Female. Gene Expression Regulation, Neoplastic. Humans. Oligonucleotide Array Sequence Analysis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 UICC.
  • (PMID = 19530251.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


69. Lu A, Li Q, Liu J: Regulatory mechanisms for abnormal expression of the human breast cancer specific gene 1 in breast cancer cells. Sci China C Life Sci; 2006 Aug;49(4):403-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BCSG1 is not expressed in normal or benign breast lesions, but expressed at an extremely high level in the vast majority of the advanced staged breast carcinomas and ovarian carcinomas.
  • Overexpression of BCSG1 in cancer cells led to significant increase in cell proliferation, motility and invasiveness, and metastasis.
  • Results showed that the Sp1 sequence in 5'-flanking region was involved in the basal transcriptional activities of BCSG1 without cell-type specificity.
  • Mutations at AP1 sites in BCSG1 intron 1 significantly reduced the promoter activity in all cell lines.
  • The 5' flanking region of BCSG1 provides the basal transcriptional activity without cell type specificity.
  • The cell type specificity of BCSG1 transcription is probably affected through intronic cis-regulatory sequences.


70. Thomas S, Chigurupati S, Anbalagan M, Shah G: Calcitonin increases tumorigenicity of prostate cancer cells: evidence for the role of protein kinase A and urokinase-type plasminogen receptor. Mol Endocrinol; 2006 Aug;20(8):1894-911
Hazardous Substances Data Bank. Calcitonin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression of human (h) calcitonin (CT) and its receptor (CTR) is localized to basal epithelium in benign prostates but is distributed in whole epithelium of malignant prostates.
  • Moreover, the abundance of hCT and CTR mRNA in primary prostate tumors positively correlates with the tumor grade.
  • We tested the hypothesis that the modulation of endogenous hCT expression of prostate cancer (PC) cell lines alters their oncogenicity.
  • The effect of modulation of hCT expression on oncogenic characteristics was examined in LNCaP and PC-3M cell lines.
  • The changes in the oncogenicity of cell sublines was assessed with cell proliferation assays, invasion assays, colony formation assays, and in vivo growth in athymic nude mice.
  • These results, when combined with our other results, that the expression of hCT in primary PCs increase with tumor grade, suggest an important role for hCT in the progression of PC to a metastatic phenotype.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16574742.001).
  • [ISSN] 0888-8809
  • [Journal-full-title] Molecular endocrinology (Baltimore, Md.)
  • [ISO-abbreviation] Mol. Endocrinol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA096534; United States / NCI NIH HHS / CA / CA96534
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / PLAUR protein, human; 0 / Plaur protein, mouse; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; 0 / Receptors, Urokinase Plasminogen Activator; 9007-12-9 / Calcitonin; EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinases; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  •  go-up   go-down


71. Mohler JL: A role for the androgen-receptor in clinically localized and advanced prostate cancer. Best Pract Res Clin Endocrinol Metab; 2008 Apr;22(2):357-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Earlier studies of androgen-receptor (AR) expression using frozen prostate tissue, and later studies using archived specimens, produced the consensus that ligand-stabilized AR is nuclear, AR expression is similar in benign epithelia and stroma, AR expression is greater in secretory epithelia than basal cells, and AR expression is more variable in prostate cancer (CaP) than in benign prostatic hyperplasia (BPH).

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cytometry. 1999 Jan 1;35(1):2-10 [10554175.001]
  • [Cites] Endocr Relat Cancer. 1999 Dec;6(4):487-502 [10730903.001]
  • [Cites] Cancer. 2000 May 15;88(10):2398-424 [10820364.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):423-7 [11212224.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2892-8 [11306464.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3550-5 [11325816.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4315-9 [11389051.001]
  • [Cites] J Natl Cancer Inst. 2001 Nov 21;93(22):1687-97 [11717329.001]
  • [Cites] Am J Pathol. 2002 Jan;160(1):219-26 [11786415.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):34-45 [11900250.001]
  • [Cites] Endocr Relat Cancer. 2002 Mar;9(1):61-73 [11914183.001]
  • [Cites] J Urol. 2002 Jul;168(1):9-12 [12050481.001]
  • [Cites] Curr Urol Rep. 2002 Feb;3(1):67-74 [12084222.001]
  • [Cites] J Clin Oncol. 2002 Jul 1;20(13):3001-15 [12089231.001]
  • [Cites] Eur J Surg Oncol. 2003 Feb;29(1):20-4 [12559071.001]
  • [Cites] J Urol. 2003 Sep;170(3):990-3 [12913756.001]
  • [Cites] J Urol. 2003 Nov;170(5):1817-21 [14532783.001]
  • [Cites] Nat Med. 2004 Jan;10(1):33-9 [14702632.001]
  • [Cites] J Clin Pathol. 2004 Feb;57(2):146-50 [14747438.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):440-8 [14760063.001]
  • [Cites] Comput Methods Programs Biomed. 2004 Jul;75(1):75-9 [15158050.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):928-34 [15223964.001]
  • [Cites] Anal Quant Cytol Histol. 1994 Dec;16(6):400-14 [7536003.001]
  • [Cites] N Engl J Med. 1995 May 25;332(21):1393-8 [7723794.001]
  • [Cites] Nat Genet. 1995 Apr;9(4):401-6 [7795646.001]
  • [Cites] Lab Invest. 1995 Aug;73(2):302-5 [7637331.001]
  • [Cites] Prostate. 1996 Apr;28(4):251-65 [8602401.001]
  • [Cites] J Urol. 1998 Mar;159(3):641-9 [9474117.001]
  • [Cites] J Urol. 1998 Feb;159(2):548-54 [9649289.001]
  • [Cites] Mol Carcinog. 1993;7(3):165-79 [8489712.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1991 Nov-Dec;1(1):21-7 [1845164.001]
  • [Cites] J Urol. 1993 Aug;150(2 Pt 1):379-85 [8326560.001]
  • [Cites] Cancer Res. 1994 Aug 1;54(15):4096-102 [7518349.001]
  • [Cites] Ann Surg Oncol. 1994 Nov;1(6):495-503 [7531602.001]
  • [Cites] Clin Cancer Res. 1996 May;2(5):889-95 [9816246.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):569-76 [10100708.001]
  • [Cites] Cancer Res. 1999 Jun 1;59(11):2511-5 [10363963.001]
  • [Cites] Cancer Metastasis Rev. 1998-1999;17(4):411-9 [10453285.001]
  • [Cites] Prostate. 2005 Apr 1;63(1):19-28 [15378523.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Cancer Cell. 2006 Oct;10(4):309-19 [17045208.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10594-602 [17079484.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 15;104(20):8438-43 [17494760.001]
  • [Cites] Prostate. 2008 Jun 1;68(8):830-8 [18324648.001]
  • [Cites] Cancer. 1996 Mar 1;77(5):934-40 [8608487.001]
  • [Cites] J Natl Cancer Inst. 1980 Aug;65(2):311-6 [6931251.001]
  • [Cites] J Urol. 1984 Apr;131(4):694-700 [6708184.001]
  • [Cites] Cancer. 1985 Jan 15;55(2):382-8 [2578085.001]
  • [Cites] Cancer. 1986 Jun 15;57(12):2351-6 [2421868.001]
  • [Cites] Science. 1988 Apr 15;240(4850):324-6 [3353726.001]
  • [Cites] Science. 1988 Apr 15;240(4850):327-30 [3353727.001]
  • [Cites] Arch Pathol Lab Med. 1988 Aug;112(8):787-90 [3395214.001]
  • [Cites] Mol Endocrinol. 1988 Dec;2(12):1265-75 [3216866.001]
  • [Cites] J Steroid Biochem. 1989;34(1-6):311-3 [2626023.001]
  • [Cites] J Pathol. 1990 Apr;160(4):329-32 [2193135.001]
  • [Cites] Ann N Y Acad Sci. 1990;595:53-66 [1695829.001]
  • [Cites] Prostate. 1990;17(4):293-300 [1701248.001]
  • [Cites] Int J Cancer. 1991 May 10;48(2):189-93 [1708363.001]
  • [Cites] J Histochem Cytochem. 1991 Jun;39(6):741-8 [1709656.001]
  • [Cites] Cancer. 1991 Jun 15;67(12):3057-64 [1710537.001]
  • [Cites] J Urol. 1992 Mar;147(3 Pt 2):798-803 [1371552.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2574-80 [7680949.001]
  • [Cites] J Urol. 1993 May;149(5):1015-9 [7683339.001]
  • (PMID = 18471792.001).
  • [ISSN] 1521-690X
  • [Journal-full-title] Best practice & research. Clinical endocrinology & metabolism
  • [ISO-abbreviation] Best Pract. Res. Clin. Endocrinol. Metab.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA077739-100006; United States / NCI NIH HHS / CA / P01 CA077739; United States / NCI NIH HHS / CA / CA 77739; United States / NCI NIH HHS / CA / P01 CA077739-100006
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / AR protein, human; 0 / Receptors, Androgen
  • [Number-of-references] 76
  • [Other-IDs] NLM/ NIHMS52370; NLM/ PMC2799036
  •  go-up   go-down


72. Tellechea O, Reis JP: Trichogerminoma. Am J Dermatopathol; 2009 Jul;31(5):480-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A case of distinctive benign follicular neoplasm previously reported under the designation of trichogerminoma is described.
  • This neoplasm and the other tumors with hair germ differentiation such as trichoblastoma and panfolliculoma seem to represent the same spectrum of hair follicle neoplasms only distinguishable by their degree of differentiation.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / pathology. Diagnosis, Differential. Humans. Immunohistochemistry. Keratins / metabolism. Male. Middle Aged. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Hair Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542926.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 68238-35-7 / Keratins
  •  go-up   go-down


73. Antony FC, Sanclemente G, Shaikh H, Trelles AS, Calonje E: Pigment synthesizing melanoma (so-called animal type melanoma): a clinicopathological study of 14 cases of a poorly known distinctive variant of melanoma. Histopathology; 2006 May;48(6):754-62
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clinical diagnosis was of melanoma in seven cases, blue naevus in three cases, benign naevus in three cases and a pigmented basal cell carcinoma in one case.
  • The histological diagnosis of PSM was predicated on the basis of an asymmetrical, predominantly intradermal tumour formed of deeply pigmented, round or short, spindle-shaped dendritic melanocytes with some degree of hyperchromatism and a single nucleolus.
  • [MeSH-minor] Adolescent. Adult. Antigens, Neoplasm. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Immunohistochemistry. MART-1 Antigen. Male. Melanocytes / chemistry. Melanocytes / pathology. Melanoma-Specific Antigens. Middle Aged. Neoplasm Proteins / analysis. Neoplasm Recurrence, Local. Nevus, Blue / metabolism. Nevus, Blue / pathology. Nevus, Pigmented / metabolism. Nevus, Pigmented / pathology. S100 Proteins / analysis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681693.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / S100 Proteins
  •  go-up   go-down


74. Uhlenhake EE, Sangueza OP, Lee AD, Jorizzo JL: Spreading pigmented actinic keratosis: a review. J Am Acad Dermatol; 2010 Sep;63(3):499-506
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It can mimic different pigmented lesions, which may be benign (eg, solar lentigo) or malignant (eg, lentigo maligna).
  • RESULTS: SPAK is a rarely reported lesion that can be difficult to distinguish from other benign and malignant pigmented lesions, including seborrheic keratosis, melanoma in situ (lentigo maligna type), and lentigo maligna melanoma.
  • Pathologically, the lesion resembles classic AK with increased basal melanization.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Hutchinson's Melanotic Freckle / pathology. Keratosis, Actinic / pathology. Precancerous Conditions / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Dermoscopy / methods. Diagnosis, Differential. Disease Progression. Female. Humans. Immunohistochemistry. Male. Neoplasm Staging. Risk Assessment

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20334953.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 35
  •  go-up   go-down


75. Ilie M, Hofman V, Pedeutour F, Attias R, Santini J, Hofman P: Oncocytic lipoadenoma of the parotid gland: Immunohistochemical and cytogenetic analysis. Pathol Res Pract; 2010 Jan 15;206(1):66-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Salivary gland oncocytic lipoadenoma is an exceptional benign tumor composed of mature adipose tissue associated with a mixture of oncocytes.
  • A 64-year-old male developed a left parotid gland, well-encapsulated tumor measuring 3.5 x 3 cm(2), showing mature fat cells associated with oncocytic changes of epithelial components.
  • Immunohistochemistry showed a dual epithelial population with ductal (positivity for AE1/AE3, CK19, CK7 antibodies) and basal-cell (positivity for p63, CK14, CK5,6 antibodies) differentiation in oncocytic areas.
  • [MeSH-minor] Disease-Free Survival. Humans. Immunohistochemistry. Lipoma / metabolism. Lipoma / pathology. Lipoma / surgery. Male. Middle Aged. Neoplasm Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier GmbH. All rights reserved.
  • (PMID = 19346081.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  •  go-up   go-down


76. Nanni S, Priolo C, Grasselli A, D'Eletto M, Merola R, Moretti F, Gallucci M, De Carli P, Sentinelli S, Cianciulli AM, Mottolese M, Carlini P, Arcelli D, Helmer-Citterich M, Gaetano C, Loda M, Pontecorvi A, Bacchetti S, Sacchi A, Farsetti A: Epithelial-restricted gene profile of primary cultures from human prostate tumors: a molecular approach to predict clinical behavior of prostate cancer. Mol Cancer Res; 2006 Feb;4(2):79-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histopathologic and molecular heterogeneity of prostate cancer and the limited availability of human tumor tissue make unraveling the mechanisms of prostate carcinogenesis a challenging task.
  • Our goal was to develop an ex vivo model that could be reliably used to define a prognostic signature based on gene expression profiling of cell cultures that maintained the tumor phenotype.
  • To this end, we derived epithelial cultures from tissue explanted from 59 patients undergoing radical prostatectomy or cistoprostatectomy because of prostate benign hyperplasia/prostate cancer or bladder carcinoma.
  • Cultures from normal/hyperplastic tissues with a prevalent luminal phenotype and from normal prostate epithelial tissue with basal phenotype (PrEC) served as controls.
  • From them, we derived an epithelial-restricted transcriptional signature that (a) differentiated normal from tumor cells and (b) clearly separated cancer-derived lines into two distinct groups, which correlated with indolent or aggressive clinical behavior of the disease.
  • [MeSH-major] Biomarkers, Tumor / genetics. Epithelial Cells / metabolism. Gene Expression Profiling. Prostatic Neoplasms / genetics
  • [MeSH-minor] Aged. Cell Differentiation. Cells, Cultured. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Phenotype. Prognosis. Prostate / metabolism. Prostatectomy. Prostatic Hyperplasia / genetics. Prostatic Hyperplasia / pathology. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16513839.001).
  • [ISSN] 1541-7786
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


77. Driemel O, Maier H, Kraft K, Haase S, Hemmer J: Flow cytometric DNA ploidy in salivary gland tumours. Oncol Rep; 2005 Jan;13(1):161-5
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study on 279 tumours of the salivary glands was conducted to analyse whether the assessment of DNA ploidy by flow cytometry may assist histopathology in discriminating benign from malignant types of tumours.
  • The group of benign tumours included 164 pleomorphic adenomas, 51 Warthin's tumours, 7 basal cell adenomas, 2 lipomas as well as 5 other different tumours.
  • All of the 229 benign tumours were diploid.
  • The malignant tumours consisted of 18 adenoid cystic adenomas, 10 mucoepidermoid carcinomas, 5 acinic cell carcinomas, 5 carcinoma in pleomorphic adenoma as well as of 12 other malignancies belonging to 7 different tumour entities.
  • In three cases which initially were taken for pleomorphic adenomas by routine histological examination, aneuploid cell populations exposed by DNA flow cytometric analysis gave rise to a closer inspection of the suspect lesions.
  • [MeSH-major] DNA, Neoplasm / analysis. Flow Cytometry. Ploidies. Salivary Gland Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15583819.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


78. Pereira PD, Lopes CC, Matos AJ, Cortez PP, Gärtner F, Medeiros R, Lopes C: Caveolin-1 in diagnosis and prognosis of canine mammary tumours: comparison of evaluation systems. J Comp Pathol; 2010 Aug-Oct;143(2-3):87-93

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In recent years there has been some controversy regarding the distribution of Cav-1 in normal and neoplastic mammary cell types, which may be attributed to different scoring systems adopted in different studies.
  • Results obtained with both scoring methods were similar, revealing absence of immunoreactivity in normal luminal epithelium and in benign neoplasms and clearly associating Cav-1 expression with malignant transformation.
  • The data suggest that Cav-1 expression is associated with highly malignant subtypes of mammary tumours (i.e. basal-like carcinoma), invasion and metastasis, thus supporting the hypothesis that it may play a major role in the epithelial-mesenchymal transition process.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma / veterinary. Caveolin 1 / metabolism. Dog Diseases / diagnosis. Mammary Glands, Animal / metabolism. Mammary Neoplasms, Animal / diagnosis
  • [MeSH-minor] Animals. Caveolae / metabolism. Dogs. Female. Immunohistochemistry. Neoplasm Invasiveness. Neoplasm Metastasis. Prognosis. Research Design. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20153868.001).
  • [ISSN] 1532-3129
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Caveolin 1
  •  go-up   go-down


79. Chung SW, Kwon SY, Jung KY, Woo JS: Synchronous double primary cancers of the unilateral parotid gland. Acta Otolaryngol; 2007 Feb;127(2):209-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A review of the literature revealed that most reported cases were either a combination of two distinct benign neoplasms or a benign neoplasm and another malignant tumor.
  • Here we report a 39-year-old woman who exhibited basal cell adenocarcinoma and mucoepidermoid carcinoma simultaneously in the left parotid gland.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17364354.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


80. Wilson ML, Elston DM, Tyler WB, Marks VJ, Ferringer T: Dense lymphocytic infiltrates associated with non-melanoma skin cancer in patients with chronic lymphocytic leukemia. Dermatol Online J; 2010;16(3):4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Basal cell carcinomas and squamous cell carcinomas in these patients may have an associated dense peritumoral leukemic infiltrate.
  • This infiltrate can lead to the diagnosis of CLL and may also obscure tumor margins and pose a challenge in the assessment of perineural tumor spread.
  • Immunohistochemical stains are useful in distinguishing leukemic B-cell infiltrates from tumor-reactive T-cell infiltrates.
  • Leukemic cells of CLL are CD20+/CD23+/CD5+/CD43+/CD3-, whereas benign reactive infiltrates are composed of CD20-/CD23-/CD5+/CD43+/CD3+ T-cells.
  • Given the paucity of symptoms in early stages of CLL, a dense lymphoid infiltrate surrounding a cutaneous neoplasm may serve as the first indication of CLL.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemic Infiltration / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Antigens, CD20 / analysis. Antigens, CD3 / analysis. Antigens, CD43 / analysis. Antigens, CD5 / analysis. B-Lymphocytes / immunology. B-Lymphocytes / pathology. Biomarkers, Tumor / analysis. Humans. Immunohistochemistry. Male. Receptors, IgE / analysis. T-Lymphocytes / immunology. T-Lymphocytes / pathology

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20233561.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD3; 0 / Antigens, CD43; 0 / Antigens, CD5; 0 / Biomarkers, Tumor; 0 / Receptors, IgE
  •  go-up   go-down


81. Bhandarkar ND, Sims HS, David O: ProEx C stain analysis in recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol; 2010 Feb;119(2):99-104
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: We evaluated the presence and pattern of ProEx C stain, a marker for the proliferative capacity of cells, in laryngeal tissues, including benign, malignant, and recurrent respiratory papilloma (RRP) specimens, and compared it to hematoxylin and eosin staining for the presence of dysplasia.
  • RESULTS: A total of 26 specimens (9 benign, 7 malignant, 10 RRP) representing 21 patients were stained.
  • Seven of 9 benign and 7 of 10 RRP specimens stained positive.
  • The benign specimens were mostly polyps.
  • The malignant specimens were either well or moderately differentiated squamous cell carcinoma, and they stained strongly and diffusely.
  • In benign and RRP specimens, the basal layer typically stained positive.
  • Other areas of epithelium stained weakly in benign specimens and variably in RRP specimens.
  • [MeSH-major] Antigens, Neoplasm / analysis. Cell Cycle Proteins / analysis. DNA Topoisomerases, Type II / analysis. DNA-Binding Proteins / analysis. Nuclear Proteins / analysis. Papilloma / chemistry. Respiratory Tract Neoplasms / chemistry
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biopsy. Cell Proliferation. Diagnosis, Differential. Humans. Immunohistochemistry. Isoenzymes. Minichromosome Maintenance Complex Component 2. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20336920.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Isoenzymes; 0 / Nuclear Proteins; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


82. Hussein MR, Elsers DA, Fadel SA, Omar AE: Clinicopathological features of melanocytic skin lesions in Egypt. Eur J Cancer Prev; 2006 Feb;15(1):64-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The lesions examined included 12 benign naevi (BN), 10 dysplastic naevi (DN), and 21 cutaneous malignant melanomas (CMMs).
  • The mean tumour thickness (Breslow) was 6+/-0.5 mm.
  • In Egypt, CMM is the third most common cutaneous neoplasm following squamous and basal cell carcinomas.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16374232.001).
  • [ISSN] 0959-8278
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


83. Kobayashi H, Ishii Y, Takayama T: Expression of L-type amino acid transporter 1 (LAT1) in esophageal carcinoma. J Surg Oncol; 2005 Jun 15;90(4):233-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND OBJECTIVES: It has been reported that amino acid transport systems play an important role in cell proliferation.
  • Their activity is increased in malignant cells compared to benign cells.
  • In this study, we investigated whether L-type amino acid transporter 1 (LAT1) is expressed in human non-cancerous esophageal mucosa and esophageal squamous cell carcinoma.
  • Histopathologically, all 30 cases were squamous cell carcinoma.
  • The ratio of cells with LAT1 expression in esophageal squamous cell carcinoma and non-cancerous esophageal mucosa was used for analysis in this study.
  • RESULTS: Non-cancerous esophageal mucosa expressed LAT1 only in the basal layer of the esophageal wall.
  • Esophageal squamous cell carcinoma expressed LAT1 throughout the tumor.
  • LAT1 expression in esophageal squamous cell carcinoma was significantly higher than that in non-cancerous esophageal mucosa.
  • LAT1 expression in esophageal squamous cell carcinoma increased as the depth of invasion progressed (T1 < T2 (P = 0.0477), T2 < T3 (P = 0.0415), T1 < T3 (P = 0.0044)), and as the tumor size increased.
  • CONCLUSION: These results suggest that LAT1 plays a significant role in cell proliferation, differentiation, and invasion in esophageal squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Esophageal Neoplasms / metabolism. Large Neutral Amino Acid-Transporter 1 / biosynthesis
  • [MeSH-minor] Aged. Animals. Cell Proliferation. Female. Humans. Immunoglobulin G / immunology. Immunohistochemistry. Lymph Nodes / pathology. Male. Middle Aged. Mucous Membrane / metabolism. Neoplasm Invasiveness. Rabbits

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15906366.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin G; 0 / Large Neutral Amino Acid-Transporter 1
  •  go-up   go-down


84. Yu N, Kozlowski JM, Park II, Chen L, Zhang Q, Xu D, Doll JA, Crawford SE, Brendler CB, Lee C: Overexpression of transforming growth factor β1 in malignant prostate cells is partly caused by a runaway of TGF-β1 auto-induction mediated through a defective recruitment of protein phosphatase 2A by TGF-β type I receptor. Urology; 2010 Dec;76(6):1519.e8-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Malignant (PC3, DU145) and benign (RWPE1, BPH1) prostate epithelial cells were used.
  • RESULTS: Basal levels of TGF-β1 in malignant cells were significantly higher than those in benign cells.
  • Blockade of TGF-β signaling resulted in a significant decrease in TGF-β1 expression in malignant cells, but not in benign cells.
  • Upon TGF-β1 treatment (10 ng/mL), TGF-β1 expression was increased in malignant cells, but not in benign cells.
  • This differential TGF-β1 auto-induction between benign and malignant cells correlated with differential activation of extracellular signal-regulated kinase (ERK).
  • Following TGF-β1 treatment, the activity of serine/threonine phosphatase and recruitment of PP2A-Bα by TβRI increased in benign cells, but not in malignant cells.
  • Inhibition of PP2A in benign cells resulted in an increase in ERK activation and in TGF-β1 auto-induction after TGF-β1 (10 ng/mL) treatment.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [Cites] EMBO J. 2007 Sep 5;26(17):3957-67 [17673906.001]
  • [Cites] EMBO Rep. 2008 Oct;9(10):990-7 [18704116.001]
  • [Cites] Int J Oncol. 2007 Feb;30(2):499-507 [17203233.001]
  • [Cites] Am J Pathol. 2006 Oct;169(4):1282-93 [17003485.001]
  • [Cites] Am J Physiol Cell Physiol. 2006 Apr;290(4):C1100-8 [16371439.001]
  • [Cites] Respir Res. 2006;7:2 [16390551.001]
  • [Cites] Cell Tissue Res. 2005 Oct;322(1):43-52 [15909166.001]
  • [Cites] Oncogene. 2000 Sep 14;19(39):4531-41 [11002426.001]
  • [Cites] Exp Cell Res. 2001 Mar 10;264(1):111-6 [11237527.001]
  • [Cites] J Immunol. 2002 Oct 1;169(7):3485-91 [12244137.001]
  • [Cites] Nature. 2003 Oct 9;425(6958):577-84 [14534577.001]
  • [Cites] Anal Biochem. 2004 Apr 1;327(1):45-54 [15033509.001]
  • [Cites] Mol Cell. 2004 Jul 23;15(2):170-1 [15260968.001]
  • [Cites] J Biol Chem. 1988 Jun 5;263(16):7741-6 [3259578.001]
  • [Cites] Mol Cell Biol. 1990 Apr;10(4):1492-7 [2108318.001]
  • [Cites] FEBS Lett. 1990 May 21;264(2):187-92 [2162782.001]
  • [Cites] Am J Respir Cell Mol Biol. 1993 Apr;8(4):417-24 [8476635.001]
  • [Cites] Science. 1995 Jun 30;268(5219):1902-6 [7604263.001]
  • [Cites] Ann Surg. 1995 Aug;222(2):146-54 [7639582.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1996 Dec;37(13):2778-82 [8977496.001]
  • [Cites] Br J Urol. 1998 Mar;81(3):403-5 [9523660.001]
  • [Cites] Mol Cell Biol. 1998 Nov;18(11):6595-604 [9774674.001]
  • [Cites] Hepatology. 1999 May;29(5):1418-24 [10216124.001]
  • [Cites] Prostate. 1999 Jun 1;39(4):285-90 [10344218.001]
  • [Cites] J Immunol. 2008 Mar 1;180(5):2757-61 [18292494.001]
  • [Cites] FASEB J. 2008 Apr;22(4):954-65 [18039929.001]
  • [Cites] Cell. 2008 Jul 25;134(2):215-30 [18662538.001]
  • [Cites] Kidney Int. 2005 Sep;68(3):972-84 [16105028.001]
  • [Cites] Clin Cancer Res. 2009 May 15;15(10):3557-67 [19447876.001]
  • [Cites] Exp Cell Res. 2007 Sep 10;313(15):3167-74 [17643425.001]
  • (PMID = 21030067.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA090386-06A2; United States / NCI NIH HHS / CA / P50 CA090386; United States / NCI NIH HHS / CA / P50 CA090386-06A2; United States / NCI NIH HHS / CA / P50CA90386
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / PPP2R2A protein, human; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptors, Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1; EC 2.7.1.11 / TGF-beta type I receptor; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 3.1.3.16 / Protein Phosphatase 2
  • [Other-IDs] NLM/ NIHMS194313; NLM/ PMC2997920
  •  go-up   go-down


85. Stewart J, Fleshner N, Cole H, Sweet J: Comparison of annexin II, p63 and alpha-methylacyl-CoA racemase immunoreactivity in prostatic tissue: a tissue microarray study. J Clin Pathol; 2007 Jul;60(7):773-80
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Staining was evaluated in benign and atrophic glands, high-grade prostatic intraepithelial neoplasia (HGPIN), and prostatic adenocarcinoma.
  • RESULTS: Diffuse cytoplasmic expression of ANXII correlated with p63 reactivity in basal cells.
  • Benign glands were positive for ANXII in 286/292 cores (98%) and negative for AMACR in all 292 cores.
  • [MeSH-major] Adenocarcinoma / metabolism. Annexin A2 / metabolism. Biomarkers, Tumor / metabolism. Prostatic Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. DNA-Binding Proteins / metabolism. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Proteins / metabolism. Organ Size. Prostate / pathology. Prostatectomy. Prostatic Intraepithelial Neoplasia / diagnosis. Prostatic Intraepithelial Neoplasia / metabolism. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Intraepithelial Neoplasia / surgery. Racemases and Epimerases / metabolism. Trans-Activators / metabolism. Transcription Factors. Tumor Suppressor Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2004 Feb;171(2 Pt 1):916-20 [14713853.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):13-9 [16330937.001]
  • [Cites] J Cell Biochem. 2004 Mar 1;91(4):852-63 [14991775.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3450-5 [14985510.001]
  • [Cites] Mod Pathol. 2004 Mar;17(3):328-48 [14976539.001]
  • [Cites] J Cell Sci. 2004 Jul 15;117(Pt 16):3539-45 [15226377.001]
  • [Cites] Mol Cancer. 2003 Oct 8;2:34 [14613585.001]
  • [Cites] Hum Pathol. 2004 Aug;35(8):1008-13 [15297968.001]
  • [Cites] Histopathology. 2004 Sep;45(3):218-25 [15330799.001]
  • [Cites] Virchows Arch. 2004 Oct;445(4):368-74 [15338305.001]
  • [Cites] J Biol Chem. 1986 Jun 5;261(16):7247-52 [2940239.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Jun;83(12):4258-62 [3012561.001]
  • [Cites] Mol Cell Biol. 1990 Jun;10(6):3216-23 [2160596.001]
  • [Cites] Differentiation. 1993 Mar;52(3):229-37 [8387039.001]
  • [Cites] Carcinogenesis. 1993 Dec;14(12):2575-9 [8269629.001]
  • [Cites] Eur J Biochem. 1994 Jun 1;222(2):313-23 [8020470.001]
  • [Cites] J Biol Chem. 1995 Jun 16;270(24):14399-404 [7782301.001]
  • [Cites] Oncol Res. 1994;6(12):561-7 [7787249.001]
  • [Cites] Prostate. 1997 Sep 15;33(1):32-7 [9294624.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Mol Cell. 1998 Sep;2(3):305-16 [9774969.001]
  • [Cites] Biochim Biophys Acta. 2000 Mar 7;1477(1-2):215-30 [10708859.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1677-82 [10749139.001]
  • [Cites] Am J Pathol. 2000 Dec;157(6):1769-75 [11106548.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6331-4 [11522620.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1397-404 [11684956.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1419-26 [11745218.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2220-6 [11956072.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):926-31 [12131161.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1588-96 [12459625.001]
  • [Cites] Oncogene. 2003 Mar 13;22(10):1475-85 [12629510.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):772-8 [12766580.001]
  • [Cites] Am J Surg Pathol. 2003 Aug;27(8):1128-33 [12883245.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):579-87 [15832080.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Jun;6(6):449-61 [15928709.001]
  • [Cites] Histol Histopathol. 2005 Jul;20(3):673-80 [15944914.001]
  • [Cites] Histopathology. 2005 Jul;47(1):1-16 [15982318.001]
  • [Cites] BJU Int. 2005 Dec;96(9):1219-23 [16287434.001]
  • [Cites] Cell Prolif. 2005 Dec;38(6):363-74 [16300650.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Biochem J. 2004 Mar 1;378(Pt 2):307-15 [14599294.001]
  • (PMID = 16916997.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Annexin A2; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Neoplasm Proteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  • [Other-IDs] NLM/ PMC1995785
  •  go-up   go-down


86. Go JW, Oh HE, Cho HK, Kang WH, Ro BI: A case of basaloid follicular hamartoma. Ann Dermatol; 2010 May;22(2):229-31

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Basaloid follicular hamartoma (BFH), uncommon rare benign neoplasm connected to the adnexal structures, presents with multiple clinical manifestations that can develop into basal cell carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Dermatol. 2005 May;44(5):361-5 [15869532.001]
  • [Cites] Arch Dermatol. 2005 Jan;141(1):60-7 [15655143.001]
  • [Cites] AMA Arch Derm Syphilol. 1952 Apr;65(4):471-6 [14902117.001]
  • [Cites] Arch Dermatol. 1993 Jul;129(7):915-7 [8323325.001]
  • [Cites] Am J Dermatopathol. 2003 Apr;25(2):130-7 [12652194.001]
  • [Cites] J Am Acad Dermatol. 1992 Aug;27(2 Pt 1):237-40 [1430363.001]
  • [Cites] J Cutan Med Surg. 2003 Sep-Oct;7(5):395-8 [14973645.001]
  • [Cites] J Am Acad Dermatol. 2003 Dec;49(6):1067-70 [14639386.001]
  • [Cites] J Am Acad Dermatol. 1993 Jul;29(1):125-9 [8315072.001]
  • (PMID = 20548923.001).
  • [ISSN] 2005-3894
  • [Journal-full-title] Annals of dermatology
  • [ISO-abbreviation] Ann Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2883435
  • [Keywords] NOTNLM ; Basaloid follicular hamartoma
  •  go-up   go-down


87. Thomas S, Muralidharan A, Shah GV: Knock-down of calcitonin receptor expression induces apoptosis and growth arrest of prostate cancer cells. Int J Oncol; 2007 Dec;31(6):1425-37
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Calcitonin (CT) and its receptor (CTR) are expressed only in basal epithelium of benign prostate and in whole epithelium of malignant prostates.
  • Also, CT and CTR mRNA levels in prostate cancers increase with an increase in tumor grade.
  • The effect of CTR modulation on the oncogenicity was evaluated by the rate of cell proliferation, invasion, colony formation and in vivo growth in nude mice.
  • This treatment also led to a remarkable decrease in endothelial cell populations in the tumors and increase in apoptotic, PCNA-negative cell populations.
  • These results suggest an important role for CT-CTR autocrine axis in the progression of localized prostate tumor to a metastatic phenotype, and offer a potential therapeutic option for invasive cancers.


88. Harvey AM, Grice B, Hamilton C, Truong LD, Ro JY, Ayala AG, Zhai QJ: Diagnostic utility of P504S/p63 cocktail, prostate-specific antigen, and prostatic acid phosphatase in verifying prostatic carcinoma involvement in seminal vesicles: a study of 57 cases of radical prostatectomy specimens of pathologic stage pT3b. Arch Pathol Lab Med; 2010 Jul;134(7):983-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Seminal vesicle invasion by prostatic carcinoma is directly associated with tumor staging; verification is challenging when the tumor demonstrates cribriform or papillary growth patterns or there are back-to-back small-gland proliferations.
  • P504S is overexpressed in prostatic carcinoma and high-grade prostatic intraepithelial neoplasia with cytoplasmic immunoreactivity. p63 has positive immunoreactivity in basal cell nuclei of benign prostatic glands.
  • Seminal vesicle epithelium from all 57 cases was negative for all 3 markers with distinct p63 nuclear staining of the basal cells.
  • Benign prostatic tissue was positive for PSA and PAP, as well as for p63, but negative for P504S.
  • It is superior to PSA or PAP when sections contain both seminal vesicle and benign glands because PSA and PAP cannot distinguish benign from malignant glands.
  • [MeSH-minor] Acid Phosphatase. Cost-Benefit Analysis. Humans. Immunohistochemistry / economics. Immunohistochemistry / standards. Male. Neoplasm Invasiveness. Neoplasm Staging. Prostate / chemistry. Prostatectomy. Staining and Labeling / economics. Staining and Labeling / standards

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20586625.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Membrane Proteins; EC 3.1.3.2 / Acid Phosphatase; EC 3.1.3.2 / prostatic acid phosphatase; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.4.21.77 / Prostate-Specific Antigen; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


89. Escaff S, Fernández JM, González LO, Suárez A, González-Reyes S, González JM, Vizoso FJ: Study of matrix metalloproteinases and their inhibitors in prostate cancer. Br J Cancer; 2010 Mar 2;102(5):922-9
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Extracellular matrix metalloproteases (MMPs) have raised an extraordinary interest in cancer research because of their potential role in basal membrane and extracellular matrix degradation, consequently facilitating tumour invasion and metastases development.
  • More than 2600 determinations on cancer specimens from 133 patients with clinically localised prostate carcinoma, 20 patients with prostatic intraepithelial neoplasia and 50 patients with benign prostate hyperplasia and controls, were performed.
  • RESULTS: When compared with benign pathologies, prostate carcinomas had higher expression of all MMPs and TIMPs.
  • CONCLUSION: The expression of MMPs and TIMPs seems to have an important role in the molecular biology of prostate carcinomas, and their expression by tumours may be of clinical interest to used as indicators of tumour aggressiveness.
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Follow-Up Studies. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Prognosis. Survival Rate. Tissue Array Analysis

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Dermatol. 1999 Mar;24(2):122-6 [10233668.001]
  • [Cites] J Clin Invest. 1999 May;103(9):1237-41 [10225966.001]
  • [Cites] Nat Rev Cancer. 2005 Jan;5(1):21-8 [15630412.001]
  • [Cites] Urol Res. 2005 Feb;33(1):44-50 [15517230.001]
  • [Cites] Am J Pathol. 2005 Apr;166(4):1173-86 [15793297.001]
  • [Cites] Thromb Haemost. 2005 Apr;93(4):770-8 [15841326.001]
  • [Cites] Cancer Cell. 2005 May;7(5):485-96 [15894268.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):215-27 [15947098.001]
  • [Cites] Br J Cancer. 2005 Jun 20;92(12):2171-80 [15928670.001]
  • [Cites] J Clin Pathol. 2005 Jul;58(7):673-84 [15976331.001]
  • [Cites] Prog Urol. 2005 Apr;15(2):250-4 [15999602.001]
  • [Cites] Crit Rev Immunol. 2005;25(6):493-523 [16390324.001]
  • [Cites] Anticancer Res. 2006 Mar-Apr;26(2A):973-82 [16619495.001]
  • [Cites] Clin Exp Metastasis. 2006;23(7-8):335-44 [17136575.001]
  • [Cites] Br J Cancer. 2007 Mar 26;96(6):903-11 [17342087.001]
  • [Cites] Neoplasia. 2007 Apr;9(4):349-57 [17460779.001]
  • [Cites] Am J Pathol. 2007 Jun;170(6):2100-11 [17525276.001]
  • [Cites] Br J Cancer. 2007 Oct 8;97(7):957-63 [17848954.001]
  • [Cites] J Biol Chem. 2008 Mar 7;283(10):6232-40 [18174174.001]
  • [Cites] Int J Oncol. 2008 Apr;32(4):757-65 [18360703.001]
  • [Cites] Oncology. 2008;75(3-4):230-6 [18852494.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):1135-49 [10694567.001]
  • [Cites] Int J Cancer. 2000 Mar 20;89(2):118-21 [10756061.001]
  • [Cites] Hum Pathol. 2000 Jul;31(7):860-5 [10923925.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12):4823-30 [11156241.001]
  • [Cites] J Cell Sci. 2001 Jan;114(Pt 1):111-118 [11112695.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1022-8 [11221828.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2189-93 [11280785.001]
  • [Cites] Br J Cancer. 2001 Apr 20;84(8):1076-83 [11308257.001]
  • [Cites] Neoplasia. 2001 Nov-Dec;3(6):459-68 [11774028.001]
  • [Cites] Oncogene. 2002 Mar 28;21(14):2245-52 [11948407.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Am J Clin Pathol. 2002 May;117(5):723-8 [12090420.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):657-72 [12209155.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):68-75 [12538453.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2003;6(1):15-26 [12664060.001]
  • [Cites] Int J Cancer. 2003 Nov 1;107(2):309-16 [12949813.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2003;6(3):217-22 [12970724.001]
  • [Cites] Clin Exp Metastasis. 2003;20(6):541-7 [14598888.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8511-5 [14679018.001]
  • [Cites] Breast Cancer Res. 2004;6(1):R24-30 [14680497.001]
  • [Cites] Am J Pathol. 2004 Apr;164(4):1131-9 [15039201.001]
  • [Cites] Oncol Rep. 2004 Jun;11(6):1187-92 [15138554.001]
  • [Cites] Cancer Cell. 2004 May;5(5):409-10 [15144947.001]
  • [Cites] Nature. 1990 Dec 20-27;348(6303):699-704 [1701851.001]
  • [Cites] J Biol Chem. 1994 Jun 17;269(24):16766-73 [8207000.001]
  • [Cites] In Vivo. 1994 May-Jun;8(3):439-43 [7803731.001]
  • [Cites] Int J Cancer. 1996 Dec 20;69(6):448-51 [8980245.001]
  • [Cites] J Biol Chem. 1997 Mar 21;272(12):7608-16 [9065415.001]
  • [Cites] Crit Rev Oncol Hematol. 1997 May;26(1):43-53 [9246540.001]
  • [Cites] Int J Cancer. 1998 Feb 20;79(1):96-101 [9495366.001]
  • [Cites] Am J Pathol. 1998 Mar;152(3):721-8 [9502414.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] J Immunol. 1998 Dec 15;161(12):6845-52 [9862716.001]
  • [Cites] J Biol Chem. 1999 Mar 12;274(11):6935-45 [10066747.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2004;7(4):327-32 [15356679.001]
  • (PMID = 20160732.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tissue Inhibitor of Metalloproteinases; EC 3.4.24.- / Matrix Metalloproteinases
  • [Other-IDs] NLM/ PMC2833257
  •  go-up   go-down


90. Taylor JA 3rd, Ristau B, Bonnemaison M, Voznesensky OS, Hegde P, Kuchel GA, Pilbeam CC: Regulation of the prostaglandin pathway during development of invasive bladder cancer in mice. Prostaglandins Other Lipid Mediat; 2009 Jan;88(1-2):36-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prostaglandin E(2) (PGE(2)) is reported to play an important role in tumor development.
  • Hence, increased COX-2 and decreased PDGH expression occurred throughout tumor development, while mPGES-1, EP2R and EP4R were elevated only before development of invasive cancer.
  • We compared expression of these genes in the malignant human urothelial cell lines, HTB-5 and HT-1376, with expression in a benign urothelial cell line, UROtsa.
  • Neither malignant cell line reproduced the complete in vivo pattern, relative to benign cells, but each showed abnormal basal expression of several of the genes downstream of COX-2, but not COX-2 itself.
  • We conclude that components involved in PGE(2) synthesis and activity are differentially regulated during bladder tumor development and the therapeutic efficacy of targeting the various components may vary with stage of tumor development.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5599-602 [11059745.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] Urol Res. 2001 Feb;29(1):20-4 [11310210.001]
  • [Cites] J Bone Miner Res. 2002 Aug;17(8):1430-40 [12162497.001]
  • [Cites] J Urol. 2003 Mar;169(3):938-42 [12576817.001]
  • [Cites] Regul Pept. 2003 Jul 15;114(2-3):101-7 [12832097.001]
  • [Cites] J Urol. 2003 Sep;170(3):985-9 [12913755.001]
  • [Cites] Urol Oncol. 2003 Jul-Aug;21(4):266-70 [12954496.001]
  • [Cites] Eur Urol. 2003 Oct;44(4):435-41 [14499677.001]
  • [Cites] J Cell Mol Med. 2003 Jul-Sep;7(3):207-22 [14594546.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):591-6 [14688410.001]
  • [Cites] Urology. 2004 Oct;64(4):637-42 [15491687.001]
  • [Cites] Anticancer Res. 1993 Jan-Feb;13(1):33-6 [8476227.001]
  • [Cites] Cancer Res. 1995 Sep 1;55(17):3785-9 [7641194.001]
  • [Cites] Cancer Res. 1997 Apr 1;57(7):1276-80 [9102213.001]
  • [Cites] J Clin Invest. 1997 Sep 15;100(6):1325-9 [9294096.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):987-90 [10070951.001]
  • [Cites] Cancer Lett. 2005 Jan 10;217(1):11-6 [15596291.001]
  • [Cites] J Biol Chem. 2005 Feb 4;280(5):3217-23 [15542609.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1092-102 [15713943.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2424-30 [10873095.001]
  • [Cites] Urology. 2000 Oct 1;56(4):671-6 [11018637.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):849-53 [11238034.001]
  • [Cites] J Intern Med. 2005 Aug;258(2):115-23 [16018788.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):713-25 [16110317.001]
  • [Cites] Gut. 2006 Jan;55(1):115-22 [16118353.001]
  • [Cites] Clin Genitourin Cancer. 2005 Dec;4(3):203-11 [16425990.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3106-13 [16540660.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2006 May;74(5):309-15 [16621493.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6649-56 [16818638.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9794-7 [17047037.001]
  • [Cites] J Urol. 2007 Mar;177(3):1163-8 [17296438.001]
  • [Cites] Exp Dermatol. 2007 May;16(5):445-53 [17437488.001]
  • [Cites] Prostaglandins Other Lipid Mediat. 2007 May;83(3):203-8 [17481556.001]
  • [Cites] BMC Cancer. 2007;7:135 [17650334.001]
  • [Cites] Carcinogenesis. 1999 Dec;20(12):2305-10 [10590224.001]
  • [Cites] J Clin Invest. 2000 Mar;105(6):823-32 [10727451.001]
  • [Cites] Oncol Rep. 2006 Feb;15(2):471-7 [16391871.001]
  • (PMID = 18834948.001).
  • [ISSN] 1098-8823
  • [Journal-full-title] Prostaglandins & other lipid mediators
  • [ISO-abbreviation] Prostaglandins Other Lipid Mediat.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK048361; United States / NIDDK NIH HHS / DK / DK048361-08; United States / NIA NIH HHS / AG / R01AG028657; United States / NIDDK NIH HHS / DK / R01 DK048361-08; United States / NIA NIH HHS / AG / AG028657-02; United States / NIDDK NIH HHS / DK / DK048361-13; United States / NIA NIH HHS / AG / R01 AG028657; United States / NIA NIH HHS / AG / R01 AG028657-02; United States / NIDDK NIH HHS / DK / R01DK48361; United States / NIDDK NIH HHS / DK / R01 DK048361-13
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Prostaglandins; 0 / RNA, Messenger
  • [Other-IDs] NLM/ NIHMS84408; NLM/ PMC2615552
  •  go-up   go-down


91. DeVilliers P, Liu H, Suggs C, Simmons D, Daly B, Zhang S, Raubenheimer E, Larsson A, Wright T: Calretinin expression in the differential diagnosis of human ameloblastoma and keratocystic odontogenic tumor. Am J Surg Pathol; 2008 Feb;32(2):256-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calretinin expression in the differential diagnosis of human ameloblastoma and keratocystic odontogenic tumor.
  • Ameloblastoma is a benign, locally aggressive epithelial odontogenic tumor that has the potential to become malignant and produce metastasis to distant sites such as lungs and kidneys.
  • The histologic presentation can be, in some instances, mistaken for keratocystic odontogenic tumor (KCOT) (formerly known as odontogenic keratocyst).
  • Gene expression profiling of ameloblastomas showed CALB2 expressed in the basal cell layer of columnar cells resembling preameloblasts, in all 5 of the ameloblastomas evaluated.
  • [MeSH-major] Ameloblastoma / diagnosis. Biomarkers, Tumor / metabolism. Jaw Neoplasms / diagnosis. Odontogenic Cysts / diagnosis. Odontogenic Tumors / diagnosis. S100 Calcium Binding Protein G / metabolism
  • [MeSH-minor] Calbindin 2. Diagnosis, Differential. Gene Expression. Gene Expression Profiling. Humans. RNA, Messenger / metabolism. RNA, Neoplasm / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18223328.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NIDCR NIH HHS / DE / DE016079
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / S100 Calcium Binding Protein G
  •  go-up   go-down


92. Sung MT, Jiang Z, Montironi R, MacLennan GT, Mazzucchelli R, Cheng L: Alpha-methylacyl-CoA racemase (P504S)/34betaE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy. Hum Pathol; 2007 Feb;38(2):332-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The staining intensities and the percentages of positively staining tumor cells were recorded.
  • All malignant acini were completely negative for both basal cell markers (34betaE12 and p63).
  • Tumor cells failed to demonstrate expression of AMACR in 14 (29%) of 49 cases.
  • Positive staining for AMACR in benign glands was not seen in any case.
  • In all cases, basal cells were strongly stained by p63 in benign acini with a mean positive percentage of 96%.
  • Similarly, basal cells in benign acini displayed moderate staining intensities for 34betaE12 in 3 (7%) of 41 cases and strong immunostaining for this marker in the remaining 38 cases (93%); the mean percentage of positive cells was 92%.
  • [MeSH-major] Adenocarcinoma / pathology. DNA-Binding Proteins / analysis. Keratins / analysis. Prostatic Neoplasms / pathology. Racemases and Epimerases / analysis. Trans-Activators / analysis. Tumor Suppressor Proteins / analysis
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Agents, Hormonal / therapeutic use. Humans. Immunohistochemistry / methods. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm, Residual. Reproducibility of Results. Transcription Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17134736.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / CK-34 beta E12; 0 / DNA-Binding Proteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 68238-35-7 / Keratins; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


93. Huang J, Yao JL, di Sant'Agnese PA, Yang Q, Bourne PA, Na Y: Immunohistochemical characterization of neuroendocrine cells in prostate cancer. Prostate; 2006 Sep 15;66(13):1399-406
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: PC tissue was stained immunohistochemically for luminal secretory cell-associated cytokeratin, basal cell markers, ki-67, androgen receptor (AR), PSA, prostate acid phosphatase (PAP), and alpha-methylacyl coenzyme A racemase (AMACR).
  • RESULTS: The NE cells are positive for AE1/AE3, Cam 5.2, and negative for basal cell markers.
  • The benign NE cells are negative for AMACR while the malignant NE cells are positive for AMACR.
  • They are post-mitotic cells but are malignant and part of the tumor.
  • [MeSH-minor] Acid Phosphatase / genetics. Acid Phosphatase / metabolism. Androgen Antagonists / pharmacology. Drug Resistance, Neoplasm. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Keratins / genetics. Keratins / metabolism. Ki-67 Antigen / genetics. Ki-67 Antigen / metabolism. Male. Phenotype. Prostate-Specific Antigen / genetics. Prostate-Specific Antigen / metabolism. Racemases and Epimerases / genetics. Racemases and Epimerases / metabolism. Receptors, Androgen / genetics. Receptors, Androgen / metabolism

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16865726.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Ki-67 Antigen; 0 / Receptors, Androgen; 68238-35-7 / Keratins; EC 3.1.3.2 / Acid Phosphatase; EC 3.4.21.77 / Prostate-Specific Antigen; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


94. Shah GV, Muralidharan A, Gokulgandhi M, Soan K, Thomas S: Cadherin switching and activation of beta-catenin signaling underlie proinvasive actions of calcitonin-calcitonin receptor axis in prostate cancer. J Biol Chem; 2009 Jan 9;284(2):1018-30
Hazardous Substances Data Bank. Calcitonin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Calcitonin, a neuroendocrine peptide, and its receptor are localized in the basal epithelium of benign prostate but in the secretory epithelium of malignant prostates.
  • Moreover, calcitonin increases tumorigenicity and invasiveness of multiple prostate cancer cell lines by cyclic AMP-dependent protein kinase-mediated actions.
  • These actions include increased secretion of matrix metalloproteinases and urokinase-type plasminogen activator and an increase in prostate cancer cell invasion.
  • Activation of calcitonin-calcitonin receptor autocrine loop in prostate cancer cell lines led to the loss of cell-cell adhesion, destabilization of tight and adherens junctions, and internalization of key integral membrane proteins.
  • These results for the first time identify actions of calcitonin-calcitonin receptor axis on prostate cancer cells that lead to the destabilization of cell-cell junctions, epithelial-to-mesenchymal transition, and activation of WNT/beta-catenin signaling.
  • The results also suggest that cyclic AMP-dependent protein kinase plays a key role in calcitonin receptor-induced destabilization of cell-cell junctions and activation of WNT-beta-catenin signaling.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Biol Ther. 2002 Jul-Aug;1(4):337-41 [12432242.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):11960-5 [11035810.001]
  • [Cites] J Cell Sci. 2003 May 15;116(Pt 10):1959-67 [12668723.001]
  • [Cites] Cancer Sci. 2003 Jul;94(7):575-81 [12841864.001]
  • [Cites] Oncogene. 2004 Apr 8;23(15):2672-2680 [14755243.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:155-63 [15153430.001]
  • [Cites] N Engl J Med. 2004 May 27;350(22):2239-46 [15163773.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4125-33 [15217949.001]
  • [Cites] Mol Cell. 2004 Aug 27;15(4):511-21 [15327768.001]
  • [Cites] Invest Urol. 1979 Jul;17(1):16-23 [447482.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Aug;79(15):4672-6 [6956885.001]
  • [Cites] Ciba Found Symp. 1988;141:48-74 [3075937.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5190-7 [1382837.001]
  • [Cites] Prostate. 1993;22(2):109-18 [7681204.001]
  • [Cites] Urol Res. 1993;21(5):359-62 [7506464.001]
  • [Cites] Endocrinology. 1994 Feb;134(2):596-602 [8299557.001]
  • [Cites] J Postgrad Med. 1993 Oct-Dec;39(4):197-201 [7996496.001]
  • [Cites] Mol Endocrinol. 1995 Aug;9(8):959-68 [7476993.001]
  • [Cites] Int J Cancer. 2001 Jan 1;91(1):46-54 [11149419.001]
  • [Cites] Prostate. 2001 Feb 1;46(2):142-53 [11170142.001]
  • [Cites] Pathol Int. 2001 Jun;51(6):452-9 [11422807.001]
  • [Cites] Mol Cell Endocrinol. 2001 Jul 5;181(1-2):69-79 [11476942.001]
  • [Cites] Cell Growth Differ. 2001 Dec;12(12):631-40 [11751458.001]
  • [Cites] J Cell Sci. 2002 Nov 15;115(Pt 22):4227-36 [12376555.001]
  • [Cites] Cancer Cell. 2002 Oct;2(4):301-14 [12398894.001]
  • [Cites] Histol Histopathol. 2005 Jan;20(1):197-203 [15578438.001]
  • [Cites] J Cell Sci. 2005 Mar 1;118(Pt 5):873-87 [15713751.001]
  • [Cites] Mol Cell Biol. 2005 Jun;25(11):4591-601 [15899862.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8519-29 [16166333.001]
  • [Cites] Int J Cancer. 2005 Nov 20;117(4):551-60 [15929083.001]
  • [Cites] Mol Cell Biol. 2005 Oct;25(20):9063-72 [16199882.001]
  • [Cites] Urol Oncol. 2005 Nov-Dec;23(6):402-6 [16301117.001]
  • [Cites] Nucleic Acids Res. 2005;33(20):6566-78 [16314317.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11649-57 [16357176.001]
  • [Cites] Cancer Biol Ther. 2005 Nov;4(11):1226-33 [16222118.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):46-51 [16397214.001]
  • [Cites] Urol Oncol. 2006 Mar-Apr;24(2):131-40 [16520277.001]
  • [Cites] Int J Cancer. 2006 Jun 1;118(11):2694-702 [16381004.001]
  • [Cites] Mol Endocrinol. 2006 Aug;20(8):1894-911 [16574742.001]
  • [Cites] Prostate. 2006 Nov 1;66(15):1664-73 [16902972.001]
  • [Cites] Clin Cancer Res. 2007 Jul 15;13(14):4042-5 [17634527.001]
  • [Cites] J Cell Physiol. 2007 Nov;213(2):374-83 [17680632.001]
  • [Cites] J Surg Oncol. 2007 Oct 1;96(5):419-23 [17874463.001]
  • [Cites] Ernst Schering Found Symp Proc. 2006;(5):27-58 [17939294.001]
  • [Cites] Int J Oncol. 2007 Dec;31(6):1425-37 [17982669.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):7003-11 [18056176.001]
  • [Cites] Cancer Cell. 2007 Dec;12(6):559-71 [18068632.001]
  • [Cites] J Cell Biochem. 2008 May 1;104(1):304-17 [17990294.001]
  • [Cites] Curr Opin Hematol. 2008 Jul;15(4):319-25 [18536569.001]
  • [Cites] Nat Cell Biol. 2003 Feb;5(2):137-42 [12545177.001]
  • [Cites] Am J Physiol. 1995 Oct;269(4 Pt 1):G467-75 [7485497.001]
  • [Cites] Urology. 1996 Mar;47(3):376-81 [8633405.001]
  • [Cites] Cell Struct Funct. 1996 Oct;21(5):381-5 [9118244.001]
  • [Cites] J Cell Biol. 1997 Jun 16;137(6):1393-401 [9182670.001]
  • [Cites] Mol Pathol. 1997 Dec;50(6):289-90 [9536277.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1603-8 [9990071.001]
  • [Cites] Oncogene. 1999 Jun 3;18(22):3376-82 [10362358.001]
  • [Cites] Int J Urol. 1999 May;6(5):240-4 [10375186.001]
  • [Cites] J Biol Chem. 1999 Aug 27;274(35):24579-84 [10455122.001]
  • [Cites] Eur J Cancer. 2004 Dec;40(18):2717-25 [15571953.001]
  • [Cites] Radiol Clin North Am. 2000 Jan;38(1):49-58 [10664666.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1671-6 [10749138.001]
  • [Cites] Genes Dev. 2000 Aug 1;14(15):1837-51 [10921899.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Oct;93(10):4135-40 [18647815.001]
  • (PMID = 19001380.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA096534; United States / NCI NIH HHS / CA / CA96534
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins; 0 / Membrane Proteins; 0 / Phosphoproteins; 0 / Receptors, Calcitonin; 0 / TJP1 protein, human; 0 / Zonula Occludens-1 Protein; 0 / beta Catenin; 9007-12-9 / Calcitonin; EC 2.7.11.26 / Glycogen Synthase Kinase 3
  • [Other-IDs] NLM/ PMC2613615
  •  go-up   go-down


95. Marchiani S, Bonaccorsi L, Ferruzzi P, Crescioli C, Muratori M, Adorini L, Forti G, Maggi M, Baldi E: The vitamin D analogue BXL-628 inhibits growth factor-stimulated proliferation and invasion of DU145 prostate cancer cells. J Cancer Res Clin Oncol; 2006 Jun;132(6):408-16
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, we have investigated the effect of the nonhypercalcemic vitamin D analogue BXL-628 on proliferation and invasive properties of the human PC cell line DU145.
  • METHODS: Cell proliferation was determined by cell counting.
  • RESULTS: BXL-628 is able to inhibit both proliferation and invasion of DU145 cells in basal conditions and in response to KGF.
  • CONCLUSIONS: Our results demonstrate that the vitamin D analogue BXL-628 is able to suppress KGF-induced proliferation and invasion of AI-PC cells in vitro, prospecting a possible use of the drug, which is currently in phase II clinical studies for benign prostatic hyperplasia, in the treatment of advanced prostate cancer.
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Humans. Male. Neoplasm Invasiveness. Signal Transduction / drug effects. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Sci. 2004 Mar 1;117(Pt 7):1235-46 [14996943.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Oct;130(10):604-14 [15258753.001]
  • [Cites] Biochim Biophys Acta. 1998 Dec 8;1436(1-2):127-50 [9838078.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Sep;6(9):727-32 [9298581.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Jul;85(7):2576-83 [10902811.001]
  • [Cites] Prostate. 2002 Jan 1;50(1):15-26 [11757032.001]
  • [Cites] Invest New Drugs. 2003 Aug;21(3):341-5 [14578682.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):455-60 [15659491.001]
  • [Cites] Exp Biol Med (Maywood). 2004 Apr;229(4):277-84 [15044710.001]
  • [Cites] Clin Chem. 1998 Apr;44(4):705-23 [9554481.001]
  • [Cites] Biochim Biophys Acta. 1997 Feb 4;1355(2):155-66 [9042336.001]
  • [Cites] Cell Growth Differ. 2000 Apr;11(4):221-9 [10775039.001]
  • [Cites] Int J Cancer. 2004 Oct 20;112(1):78-86 [15305378.001]
  • [Cites] World J Urol. 2005 Feb;23(1):28-32 [15668801.001]
  • [Cites] Science. 2004 Mar 19;303(5665):1800-5 [15031492.001]
  • [Cites] J Steroid Biochem Mol Biol. 2004 Nov;92 (4):307-15 [15663994.001]
  • [Cites] J Urol. 1999 Apr;161(4):1329-36 [10081903.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):305-8 [10667581.001]
  • [Cites] J Urol. 2005 Jan;173(1):10-20 [15592017.001]
  • [Cites] Integr Cancer Ther. 2004 Dec;3(4):349-80 [15523106.001]
  • [Cites] Endocr Rev. 2005 Aug;26(5):662-87 [15798098.001]
  • [Cites] World J Urol. 2005 Feb;23(1):1-9 [15770516.001]
  • [Cites] Lancet. 2003 Mar 8;361(9360):859-64 [12642065.001]
  • [Cites] Mol Cell Endocrinol. 2000 Jun;164(1-2):133-43 [11026565.001]
  • [Cites] Prostate. 1999 Dec 1;41(4):233-42 [10544296.001]
  • [Cites] J Lab Clin Med. 1999 Feb;133(2):120-8 [9989763.001]
  • [Cites] Eur J Endocrinol. 2004 Apr;150(4):591-603 [15080791.001]
  • [Cites] Cancer Res. 1987 Jun 15;47(12):3239-45 [2438036.001]
  • [Cites] Bull Cancer. 2005 Feb;92(2):E13-8 [15749638.001]
  • [Cites] J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):519-26 [15225831.001]
  • [Cites] Cancer Treat Res. 2003;115:145-67 [12613196.001]
  • [Cites] Endocrinology. 2003 Jul;144(7):3046-57 [12810561.001]
  • [Cites] FEBS Lett. 2000 Jul 14;477(1-2):1-7 [10899301.001]
  • [Cites] Endocrinology. 2003 May;144(5):1653-5 [12697667.001]
  • [Cites] Endocrinology. 2000 Sep;141(9):3172-82 [10965888.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Mar;129(3):165-74 [12712332.001]
  • (PMID = 16485114.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / BXL628; 126469-10-1 / Fibroblast Growth Factor 7; FXC9231JVH / Calcitriol
  •  go-up   go-down


96. Ma C, Quesnelle KM, Sparano A, Rao S, Park MS, Cohen MA, Wang Y, Samanta M, Kumar MS, Aziz MU, Naylor TL, Weber BL, Fakharzadeh SS, Weinstein GS, Vachani A, Feldman MD, Brose MS: Characterization CSMD1 in a large set of primary lung, head and neck, breast and skin cancer tissues. Cancer Biol Ther; 2009 May;8(10):907-16
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Cub and Sushi Multiple Domains-1 (CSMD1) is a tumor suppressor gene on 8p23.2, where allelic loss is both frequent and associated with poor prognosis in head and neck squamous cell carcinoma (HNSCC).
  • To understand the extent of CSMD1 aberrations in vivo, we characterized 184 primary tumors from the head and neck, lung, breast and skin for gene copy number and analyzed expression in our HNSCCs and lung squamous cell carcinomas (SCCs).
  • We detected loss of CSMD1 in a large proportion of HNSCCs (50%), lung (46%) and breast cancers (55%), and to a lesser extent in cutaneous SCCs (29%) and basal cell carcinomas (BCCs, 17%) using array-based comparative genomic hybridization (aCGH).
  • CSMD1 expression was decreased in tumors compared to adjacent benign tissue (65%, 13/20) and was likely due to gene loss in 45% of cases (9/20).
  • [MeSH-minor] Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Case-Control Studies. Chromosome Deletion. Comparative Genomic Hybridization. DNA, Neoplasm / analysis. Female. Gene Dosage. Gene Expression. Humans. Loss of Heterozygosity. Mouth Neoplasms / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism


97. Golod O, Soriano T, Craft N: Palisaded encapsulated neuroma--a classic presentation of a commonly misdiagnosed neural tumor. J Drugs Dermatol; 2005 Jan-Feb;4(1):92-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palisaded encapsulated neuroma--a classic presentation of a commonly misdiagnosed neural tumor.
  • PEN is a previously described, benign cutaneous neural tumour, with a histological appearance between that of a neurofibroma and a schwannoma.
  • Clinically, PEN is most commonly misdiagnosed as a basal cell carcinoma, a nevus, or as a neurofibroma.
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Neoplasm Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15696992.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  •  go-up   go-down


98. Birkenkamp-Demtröder K, Wagner L, Brandt Sørensen F, Bording Astrup L, Gartner W, Scherübl H, Heine B, Christiansen P, Ørntoft TF: Secretagogin is a novel marker for neuroendocrine differentiation. Neuroendocrinology; 2005;82(2):121-38
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our previous microarray-based studies identified secretagogin to be highly expressed in normal colon mucosa compared to basal expression in colon adenocarcinomas.
  • Tissues adjacent to benign hyperplasic polyps and adenomas showed a decreased number of secretagogin-expressing neuroendocrine cells.
  • Secretagogin co-localized with neuroendocrine markers (chromogranin A, neuron-specific enolase, synaptophysin) in neuroendocrine cells in crypts of normal mucosa, and in tumor cells of carcinoids.
  • Combined immunohistochemical analysis of secretagogin and FK506-binding protein 65, a protein de novo synthesized in adenocarcinomas, distinguished well-differentiated carcinoids, adenocarcinoids and undifferentiated carcinomas.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Blotting, Western. Carcinoid Tumor / metabolism. Carcinoid Tumor / pathology. Cell Differentiation / physiology. Chromogranin A. Chromogranins / metabolism. Female. Humans. Immunohistochemistry. Lung Neoplasms / secondary. Male. Microscopy, Fluorescence. Middle Aged. Neoplasm Metastasis. Oligonucleotide Array Sequence Analysis. Peptidylprolyl Isomerase / metabolism. Phosphopyruvate Hydratase / metabolism. Secretagogins. Synaptophysin / metabolism. Tacrolimus Binding Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16449819.001).
  • [ISSN] 0028-3835
  • [Journal-full-title] Neuroendocrinology
  • [ISO-abbreviation] Neuroendocrinology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Calcium-Binding Proteins; 0 / Chromogranin A; 0 / Chromogranins; 0 / SCGN protein, human; 0 / Secretagogins; 0 / Synaptophysin; EC 4.2.1.11 / Phosphopyruvate Hydratase; EC 5.2.1.- / Tacrolimus Binding Proteins; EC 5.2.1.8 / FKBP10 protein, human; EC 5.2.1.8 / Peptidylprolyl Isomerase
  •  go-up   go-down


99. Delgrange E, Sassolas G, Perrin G, Jan M, Trouillas J: Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance. Acta Neurochir (Wien); 2005 Jul;147(7):751-7; discussion 757-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Prolactinomas usually exhibit a benign course and can be safely and effectively managed by dopamine agonists (DA).
  • The aim of the present study was to determine whether histological features and markers of cell proliferation correlated to the clinical behaviour of prolactinomas and with DA resistance.
  • The prolactinomas were categorized on the basis of tumour size (48 macroadenomas), invasion of the cavernous sinus (n = 31), and resistance to bromocriptine (BRC) therapy (n = 14).
  • Seven additional parameters were studied, these being age, sex, basal prolactin (PRL) levels, the Ki-67 and PCNA labelling indices (LI), mitotic count, and cellular atypia.
  • Tumour size and invasion were related to cellular atypia and the Ki-67 LI.
  • These findings justify the long-term follow up of these tumours, and the use of surgery and/or radiotherapy if there is concern about the control of tumour growth.
  • [MeSH-minor] Adult. Aged. Drug Resistance. Female. Humans. Hypophysectomy. Ki-67 Antigen / analysis. Magnetic Resonance Imaging. Male. Middle Aged. Mitotic Index. Neoplasm Invasiveness / pathology. Neoplasm Staging. Pituitary Gland / pathology. Retrospective Studies. Sex Factors

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15971099.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Dopamine Agonists; 0 / Ki-67 Antigen; 3A64E3G5ZO / Bromocriptine
  •  go-up   go-down


100. Sabbisetti VS, Chirugupati S, Thomas S, Vaidya KS, Reardon D, Chiriva-Internati M, Iczkowski KA, Shah GV: Calcitonin increases invasiveness of prostate cancer cells: role for cyclic AMP-dependent protein kinase A in calcitonin action. Int J Cancer; 2005 Nov 20;117(4):551-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Calcitonin (CT) is synthesized and secreted in prostate epithelium, and its secretion from malignant prostates is several-fold higher than from benign prostates.
  • To identify the role of "CT System" in prostate cancer, we tested the expression of CT and CTR mRNAs in invading tumor cells of prostate cancer specimens.
  • The effect of CT on in vitro invasion of PC cell lines and on activation of gelatinases was also examined.
  • Exogenously added CT increased in vitro invasion of PC cell lines and caused a rapid, several-fold but transient increase in protein kinase A activity.
  • Rp.cAMP, a competitive inhibitor of cAMP-dependent protein kinase A, myristoylated protein kinase A inhibitory peptide (PKI) as well as the expression of dominant negative form of PKA all attenuated basal in vitro invasion of PC-3M cells, and CT could not increase in vitro invasiveness in their presence.
  • The action of CT may be mediated by protein kinase A signaling, which subsequently leads to increased cell invasion and secretion of gelatinases.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Calcitonin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15929083.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA096534; United States / NCI NIH HHS / CA / CA96534; United States / NIDDK NIH HHS / DK / DK45044
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Calcitonin; 9007-12-9 / Calcitonin; EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinases; EC 3.4.24.- / Matrix Metalloproteinases
  •  go-up   go-down






Advertisement